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POPULAR SCIENTIFIC SUMMARY 
From walking the dog to playing a sport: in our everyday life we use muscles to perform 
almost any task. Therefore, muscle weakness can severely reduce the quality of life. That is 
what happens in patients with a chronic inflammatory disease, such as rheumatoid arthritis. 
Up until today it is however not well understood how a chronic inflammation causes muscle 
weakness. 
Rheumatoid arthritis is one of the world’s most prevalent chronic inflammatory diseases. It 
affects women more often than men. Patients with rheumatoid arthritis, have an inflammation 
in their joints. Skeletal muscles are attached via the tendons to the joints which makes it 
possible to perform many different types of movements. An inflammation in the joint can 
therefore have severe effects on the muscles that surround it. In fact, scientific research has 
previously shown that the joint inflammation in rheumatoid arthritis causes the muscles to 
become weak. Muscle weakness in rheumatoid arthritis has been associated with a decrease 
in muscle mass. However, a decrease in muscle mass cannot solely explain why rheumatoid 
arthritis patients have weaker muscles than healthy persons. We measured the muscle 
strength of the legs of rheumatoid arthritis patients and of mice with arthritis and we, 
interestingly, saw that the muscle strength was decreased while the muscles were not smaller 
compared to healthy subjects. The weakness in the RA patients could neither be explained by 
a decrease in their daily activity, because we measured that the healthy individuals and RA 
patients were equally active. To understand what is happening instead, we took a closer look 
inside the muscle.  
Muscles contain many proteins, when these proteins get damaged, their normal functioning 
may change. The damage on muscle proteins can be oxidative damage which is caused by 
reactive molecules that can attack the building stones of the proteins, i.e. the amino acids. The 
reactive molecules that cause oxidative damage are called reactive oxygen species. They are 
produced under normal circumstances at many places in our body, also inside the muscles, 
and are continuously cleared away by the body’s own antioxidant system. However, when the 
production of reactive oxygen species exceeds their clearance, they can cause damage on 
protein amino acids which is called oxidative stress. Interestingly, previous research has 
shown that rheumatoid arthritis patients have more oxidative stress in their muscles which has 
been associated with muscle weakness. Up until today it was however not clear how that 
happens. 
Some of the most important proteins that regulate muscle strength are both the ryanodine 
receptor and actin. The ryanodine receptor is located at the storage place for calcium ions, the 
so-called sarcoplasmic reticulum. Calcium ions enable the muscles to produce force and the 
release of calcium from the sarcoplasmic reticulum is tightly controlled by the gatekeeper: the 
ryanodine receptor. We showed that the ryanodine receptor loses its tight control of calcium 
release when it gets damaged by oxidative stress: it increases its probability to be open, 
whereby calcium can flow through the channel. An increased open probability of the 
ryanodine receptor is associated with calcium leak from the sarcoplasmic reticulum which 
  v 
can thereby lead to decreased calcium storage and decreased muscle force production. In 
addition to the ryanodine receptor we also looked at the effects of oxidative stress on actin. 
Actin is one of the main components of the smallest muscle units that researchers can 
measure force on: the myofibrils. Our measurements showed that when myofibrils are 
damaged by oxidative stress, the force of the myofibrils decreases. To further understand the 
force producing machinery, we took a closer look at actin itself. Many actin proteins together 
form a long filament of actin, which is the centrally located filament of a myofibril. When we 
introduced oxidative damage on actin its ability to form a long actin filament was impaired.  
To further understand how oxidative stress can cause all these detrimental effects, we 
identified which exact amino acids (i.e. the protein building stones) of the ryanodine receptor 
and actin that get damaged by oxidative stress. We showed that the damage was introduced at 
specific amino acids that are located in important positions of the structure of ryanodine and 
actin. The damaged amino acids in these locations can indeed impair their normal function: 
i.e. increase the probability of that the ryanodine receptor is in an open state, decrease 
myofibrillar force and decrease the stability of actin. So the important question we then asked 
ourselves: could we identify the exact same damaged amino acids also in the ryanodine 
receptor and actin of the weaker muscles from rheumatoid arthritis patients and mice with 
arthritis? Intriguingly, yes indeed: in actin from weakened muscle of mice with arthritis and 
patients with RA we found exactly the same modified amino acids of which we have shown 
that they can cause decreased myofibrillar force and decreased actin stability. Taken together, 
we could therefore conclude that oxidative stress on actin contributes to muscle weakness in 
association with rheumatoid arthritis.  
Since the patients of our study were on conventional anti-rheumatic medication but still 
exhibited muscle weakness, the previously described results stress the need of additional 
medications that can counteract muscle weakness induced by oxidative stress in rheumatoid 
arthritis patients. There are however three important things to consider when we want to 
counteract oxidative stress in weakened muscles afflicted with RA. Firstly, and as mentioned 
before, reactive oxygen species are produced at many places in our body and our muscles, 
also under normal circumstances. Secondly, reactive oxygen species immediately react with 
everything that is near, thus most likely immediately at the places of their production. At last, 
it is important to know that our body can produce its own antioxidants that can clear reactive 
oxygen species that are produced too much and at the wrong place (e.g. near muscle proteins 
that regulate muscle force such as actin). We therefore aimed to find out which specific 
reactive oxygen species were responsible for the oxidative damage in muscles afflicted with 
arthritis. In addition, we also looked at the location of the body’s own antioxidants in 
arthritis-afflicted muscles.  
The main sources of the reactive oxygen species in muscles are considered to be the 
mitochondria and NOX2. Through inducing arthritis in mice and studying the afflicted 
muscles, we could measure the production of reactive oxygen species by these two sources. 
However, mitochondria and NOX2 appeared not to produce more reactive oxygen species in 
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muscles that were affected by arthritis. Nevertheless, when we treated the arthritic mice with 
a novel drug that can clear reactive oxygen species (a new type of antioxidant), the muscles 
that were affected by arthritis became as strong as healthy control muscles. The drug is called 
EUK-134 and can clear reactive oxygen species from mitochondria and NOX2. These results 
were even more interesting when we found out that the production of the body’s own 
antioxidants such as SOD2 and catalase, were increased in the muscles from the arthritic 
mice. Catalase was especially found more at the subcellular locations near the mitochondria 
that produce reactive oxygen species. EUK-134 has a similar function as that of SOD2 and 
catalase. Thus, although the arthritic mouse’s antioxidant capacity of their muscles was 
increased and the mitochondrial and NOX2 production of reactive oxygen species was 
decreased, extra supplementation with EUK-134 could recover their muscle force. This 
shows that the source that causes oxidative stress in arthritic muscles is different than the 
main considered sources of reactive oxygen species (i.e. the mitochondria and NOX2).  
To conclude, muscle weakness in rheumatoid arthritis patients is partly the effect of damage 
on important proteins of the muscles that regulate force. To effectively counteract muscle 
weakness caused by oxidative stress in RA, it is needed to have a good understanding of the 
sources and scavengers of reactive oxygen species inside the muscles. Novel drugs that 
specifically target oxidative stress at locations close to the important proteins can have the 
potential to improve muscle force in rheumatoid arthritis. Thereby the results of this study 
can ultimately improve the quality of life of rheumatoid arthritis patients. 
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Illustration for the popular summary: oxidative stress can cause damage on important proteins that 
regulate muscle force. Two of the most important proteins that regulate muscle force are the ryanodine receptor 
(RyR1) and actin. The ryanodine receptor is the channel that regulates calcium release from the place where it is 
stored: the sarcoplasmic reticulum (SR). Calcium enables myofibrillar force production and actin (green 
filaments, composed of many actin molecules) is an important protein structure of the myofibrils. The myofibrils 
form the force-producing units of the muscle. Damages on RyR1 and actin can be caused by reactive molecules 
called reactive oxygen species (ROS, blue balls). They are produced at specific locations inside the muscle by 
proteins such as the mitochondria (aquamarine) and NOX (orange). These damages cause decreased muscle 
force. Counteracting such damage can improve the normal function of the muscle in diseases where increased 
oxidative stress plays a role such as rheumatoid arthritis. 
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“Cogito, ergo sum” 
 
- René Descartes (Discours de la méthode)  
  1 
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ABSTRACT 
Muscle weakness is a common comorbidity of several severe diseases which results in a 
reduced independence and quality of life and for the afflicted patients. For instance, patients 
with rheumatoid arthritis (RA), a disease characterized by a chronic inflammation of the 
joints, commonly report of muscle weakness as a complication. Muscle weakness is the result 
of reduced muscle size and intramuscular impairments (i.e. intrinsic muscle dysfunction). 
However, the mechanisms whereby a chronic inflammatory condition as RA leads to muscle 
weakness is not fully understood.  
Oxidative stress due to an imbalanced production and scavenging of reactive oxygen species 
(ROS), is associated with intrinsic muscle dysfunction in RA. It can cause oxidative post 
translational modifications (oxPTMs) on RyR1 and actin which regulate muscle force 
production. In paper I, we show that mice with arthritis and patients with RA have a 
significantly decreased muscle strength which can be attributed to oxidative post-translational 
3-nitro tyrosine (3NT) and malondialdehyde (MDA) modifications on actin. Combined with 
the results of paper II, we could conclude that the oxPTMs are introduced on specific 
hotspots regions of actin which impair actin-myosin cross-bridge formation and decrease 
actin polymerization. In addition to actin, oxidative stress on the ryanodine receptor 1 (RyR1) 
is associated increased RyR1 open-probability and Ca2+ leak which can ultimately lead to 
muscle weakness. In paper III we showed that specific 3NT and MDA modifications on 
RyR1 increase the channel’s open probability and lead to dissociation of the RyR1 stabilizing 
protein FKBP12. The results together stress the need to study how muscle weakness caused 
by oxidative stress can be counteracted. Therefore, we in paper IV identified the effect of 
arthritis on the sources and scavengers of ROS in skeletal muscle. In paper IV we showed 
that while the expression of ROS scavengers SOD2, catalase and GPX1 was increased, 
treatment of mice with the SOD/catalase mimetic EUK-134 significantly restored muscle 
force. All results together stress the importance of targeted therapy against oxidative stress-
induced muscle weakness in RA. 
  
 2 
LIST OF SCIENTIFIC PAPERS 
 
I. Oxidative hotspots on actin promote skeletal muscle weakness in 
rheumatoid arthritis. 
JCI Insight, 2019, 5. piii:126347. doi:1172/jci.insight.126347 
 
MAARTEN M STEINZ, Malin Persson, Bejan Aresh, Karl Olsson, Arthur J. 
Cheng, Emma Ahlstrand, Mats Lilja, Tommy R. Lundberg, Eric Rullman, 
Kristina Ängeby Möller, Katalin Sandor, Sofia Ajeganova,Takashi Yamada, 
Nicole Beard, Björn C.G. Karlsson, Pasi Tavi, Ellinor Kenne, Camilla I. 
Svensson, Dilson E. Rassier, Roger Karlsson, Ran Friedman, Thomas 
Gustafsson, and Johanna T. Lanner 
 
II. Force generated by myosin cross-bridges is reduced in myofibrils 
exposed to ROS/ RNS 
American Journal of Physiology Cell Physiology, 2019, 
https://doi.org/10.1152/ajpcell.00272.2019 
 
Malin Persson, MAARTEN M STEINZ, Håkan Westerblad, Johanna T 
Lanner and Dilson E Rassier 
 
III. Oxidative MDA and nitration modifications on RyR1 lead to higher open 
probability and FKBP12 dissociation 
Manuscript 
 
MAARTEN M STEINZ; Nicole Beard; Johanna T. Lanner 
 
IV. The role of ROS sources and scavengers in skeletal muscle of mice with 
arthritis 
Manuscript 
 
MAARTEN M STEINZ*, Michaeljohn Kalakoutis*, Anna-Lena Boller, Theresa 
Mader, George G. Roodney, Pasi Tavi, Johanna T. Lanner 
  3 
CONTENTS 
1 Background .................................................................................................................... 10 
1.1 Introduction .......................................................................................................... 11 
1.1.1 Rheumatoid arthritis ................................................................................ 11 
1.2 Skeletal Muscle.................................................................................................... 12 
1.2.1 The structure of the skeletal muscle ....................................................... 12 
1.2.2 Excitation-contraction coupling and force production ........................... 13 
1.2.3 Skeletal muscle weakness associated with RA ...................................... 14 
1.3 Oxidative stress .................................................................................................... 15 
1.3.1 Oxidative post-translational modifications............................................. 15 
1.3.2 Tyrosine nitration .................................................................................... 15 
1.3.3 Malondialdehyde adducts ....................................................................... 16 
1.3.4 Effects of oxidative post-translational modifications on skeletal 
muscle proteins ........................................................................................ 17 
1.3.5 Oxidative modifications on myofibrils and actin ................................... 17 
1.3.6 Oxidative modifications on RyR1 .......................................................... 18 
1.4 Sources & scavengers of ROS in skeletal muscle .............................................. 19 
1.4.1 Mitochondria as a source of ROS ........................................................... 20 
1.4.2 ROS producers NOX2, NOS and PLA2 ................................................ 21 
1.4.3 ROS scavengers SOD, catalase and GPX1 ............................................ 21 
1.5 Counteracting muscle weakness in RA .............................................................. 23 
2 Aims ............................................................................................................................... 26 
3 Methodology.................................................................................................................. 28 
3.1 Animal model and human subjects ..................................................................... 29 
3.1.1 Study approval ......................................................................................... 29 
3.1.2 CFA induced arthritis .............................................................................. 29 
3.1.3 RA patients and healthy control persons ................................................ 29 
3.2 Measurements of force and physical activitiy .................................................... 29 
3.2.1 Ex vivo force measurements ................................................................... 29 
3.2.2 Dissected single FDB fiber force measurements ................................... 30 
3.2.3 Myofibrillar force measurements ........................................................... 30 
3.2.4 Biodex force measurements .................................................................... 30 
3.2.5 Accelerometry ......................................................................................... 31 
3.3 Molecular biology ............................................................................................... 31 
3.3.1 Purification of SR extracts and single RyR1 channels .......................... 31 
3.3.2 Immunoblots ............................................................................................ 31 
3.3.3 RNA isolation .......................................................................................... 32 
3.3.4 Reverse transcription ............................................................................... 32 
3.3.5 RT-PCR ................................................................................................... 32 
3.4 Actin polymerization and single channel recordings  ........................................ 32 
3.4.1 Actin polymerization assay ..................................................................... 32 
3.4.2 Single RyR1 channel recordings ............................................................ 33 
 4 
3.5 Analytical analysis of protein biology ................................................................ 33 
3.5.1 Mass spectrometry .................................................................................. 33 
3.5.2 Chimera 3D protein modeling ................................................................ 34 
3.5.3 Molecular dynamic simulations .............................................................. 34 
3.6 Measurements of ROS sources and ROS scavengers ........................................ 34 
3.6.1 Electroporation of roGFP for live cell imaging of ROS ........................ 34 
3.6.2 Single muscle fiber dissociation ............................................................. 34 
3.6.3 RoGFP live cell imaging for ROS production ....................................... 35 
3.6.4 Immunofluorescent imaging of ROS scavengers................................... 35 
3.6.5 Catalase activity assay ............................................................................ 35 
3.7 Statistics ............................................................................................................... 35 
4 Results and discussion ................................................................................................... 38 
4.1 Oxidative modifications on actin promote muscle weakness in RA (Paper 
I & II) ................................................................................................................... 39 
4.1.1 Decreased force of muscle from mice with arthritis .............................. 39 
4.1.2 Altered Ca2+ handling of muscles from mice with arthritis ................... 39 
4.1.3 Decreased force of muscles from patients with RA ............................... 40 
4.1.4 Declined myofibrillar force .................................................................... 41 
4.1.5 Compromised actin polymerization ....................................................... 42 
4.1.6 3NT and MDA modifications on actin ................................................... 43 
4.1.7 3NT and MDA modifications on actin from RA patients ..................... 43 
4.2 Oxidative modifications increase the open probability of RyR1 which is 
associated with RA-induced muscle weakness (Paper III) ................................ 45 
4.2.1 Increased RyR1 open probability ........................................................... 45 
4.2.2 3NT and MDA modifications on RyR1 ................................................. 45 
4.2.3 FKBP12 dissociation .............................................................................. 47 
4.2.4 3NT and MDA modifications on RyR1 from muscle affected by 
arthritis ..................................................................................................... 48 
4.3 Sources and scavengers of ROS in skeletal muscles affected by arthritis 
(Paper IV) ............................................................................................................ 48 
4.3.1 Decreased expression of mitochondrial complexes ............................... 48 
4.3.2 Increased expression of scavengers SOD2, catalase and GPX1 ........... 49 
4.3.3 Altered subcellular location of ROS scavenger in muscles affected 
by arthritis ................................................................................................ 49 
4.3.4 No increase of ROS production from mitochondria or NOX2 .............. 50 
4.3.5 Treatment of mice with arthritis with the SOD2/ catalase-mimetic 
EUK-134 restores muscle force .............................................................. 51 
4.3.6 The sources and scavengers of ROS in skeletal muscles affected 
by RA: further studies are needed .......................................................... 52 
5 Conclusions ................................................................................................................... 54 
6 Acknowledgements ....................................................................................................... 56 
7 References ..................................................................................................................... 60 
  5 
 
LIST OF ABBREVIATIONS 
 
AA Arachidonic Acid   
ACPA Anti-Citrinullated Protein Antibodies  
ACR American College of Rheumatology  
AIA Adjuvant Induced Arthritis  
CaM Calmodulin  
CaMBD CaM Binding Domain 
CaMKII Calmodulin-Dependent Protein Kinase II  
CFA Complete Freund's Adjuvant  
CIA Collagen Induced Arthritis  
CI-IV Mitochondrial Complex I-IV 
Cn Copernicium  
CoQ Co-enzyme Q10  
CSA Cross-Sectional Area  
CsMS Cesium Methane Sulfonate 
Cu Copper  
D Aspartic Acid  
DAS Disease Activity Score  
DHPR Dihydropyridine Receptor  
DMARDs  Disease-Modifying Anti-Rheumatic Drugs 
DMF Dimethyl Fumarate  
DNP Carbonylation  
DR2 Divergent Region Two 
DTT  Dithiothreitol 
E Glutamic Acid  
 6 
ECC Excitation-Contraction Coupling 
EDL Extensor Digitorum Longus  
eNOS Endothelial NOS 
EULAR European League Against Rheumatoid Arthritis 
F-actin Filamentous Actin 
fapp Rate of Cross Bridge Attachment  
FCB  Force per Cross Bridge 
FDB Flexor Digitorum Brevis   
FKBP12 FK506-binding Protein 12  
FMN Flavine Mononucleotide 
gapp Rate of Cross Bridge Detachment  
GPX Glutathione Peroxidases  
GSH Glutathione  
GSSG Glutathione Disulfide  
H Histidine  
H2O2 Hydrogen Peroxide 
HMOX Heme Oxygenase  
iNOS Inducible NOS  
JSol Junctional Solenoid  
K Lysine  
LOO• Lipid Peroxide Radical 
LOOH Lipid Hydroperoxide 
MDA Malondialdehyde 
Mn Manganese  
N Asparagine  
nCB Number of Cross Bridges 
nNOS Neuronal NOS  
  7 
NOS Nitric Oxide Synthases  
NOX NADPH Oxidases 
NQO NAD(P)H Dehydrogenases  
NTD N-terminal Domain  
O2
•- Superoxide 
ONOO- Peroxynitrite  
oxPTM Oxidative Post-Translational Modifications 
PBS Phosphate Buffered Saline 
PKA Protein Kinase A 
PLA2 Phospholipase 2  
PRX Peroxiredoxins  
pVSD Pseudo Voltage Sensitive Domain 
Q Glutamine  
Qi Reduction Side of Co-enzyme Q 
Qo Oxidation Side of Co-enzyme Q 
R Arginine  
RA Rheumatoid Arthritis  
RET Reverse Electron Transport  
RMSF Root Mean Square Fluctuations  
roGFP Reduction-oxidation Sensitive Green Fluorescent Protein  
ROS Reactive Oxygen Species  
RY1&2/3&4 RyR Repeat Domains 1&2/3&4 
RyR1 Ryanodine Receptor 1 
SASA Solvent-Accessible Surface Area  
SCLP Shell-Core Linker Peptide  
SD Subdomain 
SERCA Sarcoplasmic Reticulum Ca2+ ATPase  
 8 
SIN-1 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium Chloride 
SNO S-Cysteine-Nitrosylation  
SOD Superoxide Dismutase  
SPRY spIA Kinase and RyR Domain 
SR Sarcoplasmic Reticulum 
TaF Thumb and Forefinger 
TRX Thioredoxins  
TT T-Tubulus 
Y Tyrosine 
Zn Zinc  
3NT 3-Nitro Tryosine 
6-TM Six-Transmembrane 
  
  9 
  
 10 
1 BACKGROUND 
  
  11 
1.1 INTRODUCTION 
 
Muscle weakness is a risk factor for negative health outcomes associated with loss of 
independence and reduced quality of life since most of our daily activities require muscular 
work (1). Muscle weakness is present in many diseases, including rheumatoid arthritis (RA) 
(2-6), cancer (7) and sepsis (8), which are diseases also associated with an increased (chronic) 
local or systemic inflammation. Muscle weakness can be the combined result of reduced 
muscle size (atrophy) and intramuscular impairments (intrinsic muscle dysfunction). 
Interference with the excitation-contraction coupling (ECC), the force producing machinery 
(i.e. cross-bridge cycling), and/or accumulation of non-contractile tissue (e.g. fat, fibrosis) 
can all be contributing factors to intrinsic muscle dysfunction that reduces the capacity of the 
muscle to generate power. Disease-induced muscle weakness is commonly attributed to 
reduced muscle mass (9-11), however, research from our group and others has shown that a 
decrease in muscle mass cannot solely explain muscle weakness associated with a chronic 
inflammatory disease  (2, 3, 12). In fact, the mechanisms whereby inflammation leads to 
muscle weakness is still unclear. 
The aim of this thesis is to define the molecular mechanisms behind muscle weakness 
associated with the chronic inflammatory condition of RA, which ultimately could lead to 
improve the quality of life of patients suffering from muscle weakness and fatigue.  
1.1.1 Rheumatoid arthritis  
 
Rheumatoid arthritis is one of the most common chronic inflammatory diseases and affects 
primarily women in the age of 40-50 years (13-15). The disease is characterized by a chronic 
inflammation of the joints with systemically elevated levels of e.g. circulating cytokines (e.g. 
tumor necrosis factor α (TNF-α), interleukine-6 (IL-6), monocyte chemoattractant protein 1 
(MCP1), and interleukin-1 (IL-1))(16, 17), autoantibodies to immunoglobulin G (Rheumatoid 
Factor, RF) and autoantibodies against citrinullated proteins (anti-citrinullated protein 
antibodies, ACPA’s) (15-18). When RA is left untreated it will ultimately lead to severe 
damage and destruction of the joints (15). It has been shown that the quality of life and work 
productivity in RA patients is significantly reduced in association with physical limitations 
(1). Patient with RA indeed suffer from muscle weakness and fatigue, including a reduction 
in muscle strength without corresponding loss of muscle mass (2),(3),(4, 12, 19-21). 
Moreover, a decreased physical ability in RA is associated with elevated levels of pro-
inflammatory cytokines as IL-1β and IL-6 (18). Up until today however, little molecular 
insight is available on how a chronic inflammation as RA induces muscle weakness. In this 
thesis we elucidated the skeletal muscle capacity in mice afflicted with arthritis and in 
patients with RA.  
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1.2 SKELETAL MUSCLE 
1.2.1 The structure of the skeletal muscle 
There are three different types of muscle in the body: cardiac muscle, smooth muscle and 
skeletal muscle. The human body consist of ~35-40% of skeletal muscle relative to body 
weight (22). Skeletal muscles are essential for our ability to move and one of its major 
purposes is to produce force (23, 24). A given muscle is made of hundreds to thousands of 
multinucleated muscle fibers bundled together (Figure. 1) (23, 24). The muscle bundles and 
the muscle itself are surrounded by connective tissue called the perimysium and epimysium, 
respectively (24). Looking further into the structure of each muscle fiber, it can be observed 
that it consists of thousands of myofibrils (23), which are repeats of thick and thin filaments 
that form the functional unit called the sarcomere (Figure. 2) (23). The sarcomere’s thick 
filaments consist of myosin and other proteins such as titin (25), whereas the thin filaments 
are composed of troponin and tropomyosin that are wrapped around the centrally located 
actin filament (F-actin) (23, 25). The F-actin filament is composed of actin monomers (G-
actin) (26).  
 
 
Figure 1. Illustration of the composition of a muscle. A muscle is made of muscle bundles that each 
consist of hundreds to thousands of muscle fibers (here only illustrated a few for simplicity of the 
picture). Each muscle fibers contains many myofibrils which are repeats of many well-organized 
sarcomeres. 
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Figure. 2 The organization of the muscle’s sarcomere. Each sarcomere spans from one z-line 
(shown in blue) to the other z-line and is composed of thick filaments that contain myosin (shown in 
brown), and thin filaments that contain as actin (shown in green). The middle of the sarcomere is the 
M-line. Other bands that can be distinguished are the I-band, A-band and H-zone as illustrated above. 
The interaction of actin and myosin results in force production of the muscle. Repeats of sarcomeres 
form a myofibril, which is one of the smallest functional units that force can be measured on in-vitro. 
 
1.2.2 Excitation-contraction coupling and force production 
Skeletal muscle force is generated through the excitation-contraction coupling (ECC) and the 
interaction of contractile proteins in the force producing machinery (cross-bridge cycling) 
(Figure. 3) (27). The concept of ECC was first postulated in 1952 by Alexander Sandow 
(28). When an action potential is propagated to the t-tubules of the SR it triggers the voltage-
dependent dihydropyridine receptor (DHPR) activation in the sarcolemma. DHPR 
mechanically interacts with the ryanodine receptor 1 (RyR1) which is in the membrane of the 
sarcoplasmic reticulum (SR) inside the muscle cell (29). Activation of the DHPR causes the 
RyR1 opening and the Ca2+ is released from the SR into the cytoplasm (29). The intracellular 
Ca2+ concentration ([Ca2+]i) increases and Ca
2+ interacts with troponin causing displacement 
of the tropomyosin filaments along actin. This opens the site where the myosin head can bind 
to the actin filament. During the power stroke in the cross-bridge cycling, the myosin head 
will change its conformation and pull in actin, which thereby enables force production (25, 
30). Ca2+ is pumped back into the SR by the SR Ca2+ ATPase (SERCA) which allows the 
muscle to relax (19, 29). The [Ca2+]i-force relationship is sigmoidal which reaches a plateau 
where maximum force is reached at high [Ca2+]i (31). In mouse muscle fibers under resting 
conditions the [Ca2+]i is ~50-100 nM and when activated, [Ca
2+]i increases to ~1 μM (31). 
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Figure 3. Illustration of excitation-contraction coupling (ECC). ECC starts with an action potential 
that reaches the t-tubules of a muscle fiber. This causes mechanical interaction of dihydropyridine 
receptors (DHPR, shown in pink) with the ryanodine receptor 1 (RyR1, shown in blue) of the 
sarcoplasmic reticulum (SR). Thereby Ca2+ will be released via RyR1 into the sarcoplasm which 
enables actin-myosin cross-bridge formation and thereby force production of the muscle. Ca2+ is 
pumped back into the SR by the SR Ca2+ ATPase (SERCA). 
 
1.2.3 Skeletal muscle weakness associated with RA 
A decrease in muscle mass in patients with a chronic inflammatory disease as RA, is 
associated with a decrease in muscle strength (11, 32, 33). However, Helliwell & Jackson 
showed already in 1994 that a decrease in fore-arm muscle mass of RA patients can only 
explain 40% of the decrease in fore-arm grip strength (12). Later, more studies have shown 
that muscle weakness due to a chronic inflammation cannot solely be explained by a decrease 
in muscle mass (2),(3),(4, 19-21). Based on these findings, it was postulated that intrinsic 
muscle dysfunction may be an important contributor to muscle weakness accompanying RA 
(19). More specifically, they can be an effect of (i) decreased Ca2+ release from the SR by 
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RyR1, (ii) decreased sensitivity of myofibrils to Ca2+ and (iii) a decreased ability of actin and 
myosin to generate myofibrillar force (19). Concerning the latter in more detail: myofibrillar 
isometric force production depends on: (a) the number of actin-myosin cross bridges (nCB), 
(b) the force per cross bridge (FCB), (c) the rate of cross bridge attachment (fapp) and (d) the 
rate of cross-bridge detachment (gapp) (34, 35).  
1.3 OXIDATIVE STRESS 
Oxidative stress is a term to describe to maladaptive effects of an imbalanced production of 
reactive oxygen and nitrogen species (ROS) at a specific subcellular place, time and amount 
(36). ROS can be free radicals, i.e. superoxide (O2
•-), peroxynitrite (ONOO•-) and hydroxyl 
radical (OH•), or non-free radicals, i.e. hydrogen peroxide (H2O2) which can form OH
• (37). 
ROS can cause oxidative post-translational modifications (oxPTM) of amino acid residues of 
proteins. Oxidative stress has been shown to be part of the pathophysiology of RA (2, 3, 38-
40). 
1.3.1 Oxidative post-translational modifications  
OxPTM on skeletal muscle proteins caused by oxidative stress can be reversible or stable 
changes of amino acids. There are several types of oxPTMS as nitrosylation (SNO), 
carbonylation (DNP), nitration (NT) and malondialdehyde adducts (MDA). Nitrosylation is 
an oxPTM occurring mostly on cysteine residues, i.e. S-nitrosylation, which can be reversed 
enzymatically by e.g. glutaredoxin (GPX) or thioredoxin (TRX) (41). On the other hand, 
carbonylation, nitration and addition of a malondialdehyde (MDA) adduct are more stable 
changes to amino acids (41-45). Hallmarks of both nitration and MDA adducts have been 
found in RA patients (38, 39) and rodents with arthritis (2, 3). Due to the stability of nitration 
and MDA adducts, progressive protein damage may occur (46). It is for these reasons we 
have focused on these two types of modifications in relation with oxidative stress and muscle 
weakness associated with RA.  
1.3.2 Tyrosine nitration 
The amino acid tyrosine (Y) contains a phenol group that plays a central role in nitration. One 
of the first biological evidences for 3-nitrotyrosines (3NT) (Figure. 4) came from Ohshima et 
al. in 1990, showing that rats had increased levels of nitrated proteins in their plasma after 
injection of the nitrating compound tetranitromethane (47). A push for research on nitration 
of tyrosine residues in a biological setting came after Beckman et al. showed that ONOO- is a 
highly reactive intermediate that can be formed during the biological reaction of NO with O2
•- 
(48). The formation reaction of ONOO- has a fast rate constant between 7.5 and 21 x 109 M-1 
s-1 (49). It has later become clear that the biological formation of 3NT happens in multiple 
steps (43). ROS can promote the formation of a tyrosine radical (Tyr•) which can react with 
ONOO- derived radicals, leading to addition of a nitro-group on the third C position of the 
phenol ring of tyrosine (43). Increased 3NT levels have been observed on skeletal muscle 
actin of mice and rats with arthritis (2, 3). Tyr• can also react with another Tyr• to form 3, 3’-
dityrosine (43) and it has been shown that nitrated proteins can cause formation of protein 
 16 
aggregates (50). Actin aggregates have previously been found in rat models of high oxidative 
stress, as well as in a rat model of arthritis (3, 51). In addition to actin, RyR1 contains many 
tyrosine residues which could be susceptible for nitration, and 3NT modifications have been 
found on the RyR1 complex in mice with arthritis (2).  
 
Figure 4. Tyrosine nitration (3-NT). From left to right: tyrosine, tyrosine radical, 3-nitrotyrosine 
(3NT) and an illustration of 3NT within a 3-dimensional protein crystal structure (NO2, +46 Da, 
shown in pink). 
1.3.3 Malondialdehyde adducts 
MDA is a reactive aldehyde which can react with basic amino acids such as Histidine (H), 
Lysine (K), Arginine (R), Glutamine (Q) and Asparagine (N) (Figure. 5) (42, 52). MDA is 
generated enzymatically during the synthesis of pro-inflammatory eicosanoids (i.e. 
thromboxane A2), and non-enzymatically during lipid peroxidation (42). Lipid peroxidation 
takes place in three steps and in the first initiation step, a lipid radical (L•) is formed due to 
the reaction of ROS with the hydrogen of the allyl group next to the carbon-carbon double 
bound of an unsaturated lipid. Then, in the propagation step, L• reacts with oxygen and forms 
a lipid peroxide radical (LOO•). LOO• reacts with another lipid molecule to form a new L• 
and lipid hydroperoxide (LOOH). In the terminating step LOO• from the propagation step 
will react with an antioxidant such as vitamin E to form a non-radical LOOH (42). LOO• can 
alternatively cyclize to and endoperoxide which, by cleavage, will form MDA. Intriguingly, 
increased levels of auto-antibodies against MDA-modified proteins have been found in serum 
and the synovium from RA patients (38, 39, 53).  
  
  17 
 
Figure 5. Malondialdehyde (MDA) adducts on arginine, glutamine, lysine, histidine and 
asparagine.  From left to right top row: Arginine-MDA (R/MDA), Glutamine-MDA (Q/MDA), 
Lysine-MDA (K/MDA). From left to right bottom row: Histidine-MDA (H/MDA), Asparagine 
(N/MDA) and illustration of N/MDA within a 3-dimensional protein crystal structure (C3H3O, +54 
Da, shown in pink). The proposed MDA modifications are adapted from Zhao et al. (52). 
1.3.4 Effects of oxidative post-translational modifications on skeletal muscle 
proteins 
The effect of oxPTM on skeletal muscle force production have been examined by incubating 
muscle with various oxidants. Hydrogen peroxide (H2O2) (54), peroxynitrite (ONOO
-) and 
the NO and O2
-• donor 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium chloride (SIN-1) (55) 
have been used to study the direct effects of oxidative stress on skeletal muscle force 
production. SIN-1 forms ONOO- at a linear relation to its original concentration (56). 
Sustained incubation of skeletal muscle fibers with H2O2 results in decreased force 
production and the force decline was diminished after adding the reducing agent DTT (54). A 
study by Dutka et. al in 2011(55), showed that force of skinned muscle fibers was decreased 
after addition of ONOO- or SIN-1. The reduced force of single muscle fibers after SIN-1 
incubation has been attributed to a decline in Ca2+ sensitivity of the myofibrils (55, 57). These 
studies report about observed changes in force production in the presence of oxidative agents. 
However, they do not explain the underlying molecular details of ONOO- -induced 3NT and 
MDA modifications on contractile muscle proteins that are essential for force production. In 
this thesis, the functional effects of introducing 3NT and MDA modifications were clarified 
in relation to the force production by myofibrils, the polymerization of actin and the open 
probability of RyR1.  
1.3.5 Oxidative modifications on myofibrils and actin 
The myofibrils are the force-generating machinery of the muscle. A major component of 
the myofibrils is the centrally located actin filament. Previous studies have shown that actin is 
a primary target for oxidative 3NT modifications (58, 59) which is associated with muscle 
weakness in arthritis (2, 3). Moreover, oxPTMs on actin have been found in association with 
Alzheimer’s disease (60), Freidrich’s ataxia (61), and inflammation and pain (62). Actin 
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filaments have a helical structure with a fast (barbed) and slow (pointed) end. The actin 
filament is formed through polymerization of actin monomers (G-actin) (Figure. 6). The 
structure of G-actin was first described in 1990 (63) and improvements in techniques that 
determine the crystal structure of a protein, have now given a detailed picture of what 
monomeric G-actin and its four subdomains look like 3-dimensionally (64, 65). G-actin 
polymerization to F-actin, is an allosteric process and is coupled to ATP hydrolysis (26, 66, 
67). Assembly of ATP-bound G-actin at the barbed end, is followed by nucleotide hydrolysis 
and dissociation of ADP-bound G-actin at the pointed end (68). ADP-bound actin can 
undergo nucleotide exchange to form new ATP-bound actin that can bind to the barbed end 
of the actin filament again (66, 67).  
 
Figure 6. Illustration of actin-polymerization. Actin forms the centrally located filament of the thin 
filaments of the myofibrils’ sarcomeres. The actin filament (F-actin), as illustrated above, is composed 
of many actin monomers (G-actin). The polymerization of G-actin to F-actin is a continuous process 
of addition of ATP-actin on the barbed end of the filament and dissociation of ADP-actin on the 
pointed end of the filament. ATP hydrolysis to ADP-Pi actin happens when ATP-bound actin moves 
towards the pointed end. ADP-actin can subsequently exchange ADP for ATP so that it can bind the 
filament again. 
Due to the continuous process of polymerization, the actin filament is polymorphic and the 
G-actin monomers within an actin filament are in contact with neighboring actin monomers 
and with myosin (69, 70). It is for these reasons that protein modifications in the form of 
oxPTMs are likely to affect actin polymerization and myofibrillar force production. The 
direct effects of oxidative 3NT and MDA modifications on myofibrillar force and actin 
polymerization have up until today not been elucidated and neither is it known if they can 
cause muscle weakness in muscles affected by RA. We studied the effects of oxPTMs 3NT 
and MDA on myofibrillar force and actin polymerization in muscles from mice with arthritis 
and patients with RA.  
1.3.6 Oxidative modifications on RyR1 
Muscle force production is Ca2+ dependent and increases with increased Ca2+ release (71). 
Thus, for myofibrils to be able to contract, Ca2+ release from the SR is needed. The RyR1 
complex tightly regulates Ca2+ release from the SR(72). Many researchers have aimed to 
unravel the structure of RyR1(73-77) and thanks to improved methodology with cryo-EM, 
more details of crystal structure of RyR1 have become available (73, 74, 78). RyR1 has a 
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large cytosolic shell and relatively small trans membranous pore region with each RyR1 
monomer containing 21 specific subdomains (73, 74).  
RyR1 has gained a lot of interest when it comes to understanding the functional effects of 
post-translational modifications on RyR including phosphorylation, nitrosylation and other 
oxidative modifications (7, 45, 79, 80). There are three isoforms of RyR (RyR1, 2 &3) of 
which the ~2.2MDa big homotetrameric and in the skeletal muscle main expressed isoform is 
RyR1 (29, 72). The expression of RyR1 in skeletal muscle was found in 1989 by Takeshima 
et al. (81) and Zorzato et al. in 1990 (82). RyR1 forms a super-complex with other regulatory 
proteins, such as calmodulin (CaM) and the FK506-binding protein 12 (FKBP12) (29). In 
addition, other ions and proteins are known to regulate the activity of RyR1, such as Ca2+, 
Mg2+, calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA) (29). 
Many studies have shown that dissociation of FKBP12 in association with increased levels of 
oxPTMs on the RyR1 complex (7, 29, 83-85). However, only a few studies have been able to 
directly link a specific modified amino-acid residue to altered RyR1 gating (86-88). One 
post-translational modification on RyR1 that indeed can alter the function of RyR1, is 
nitrosylation of Cystein3635, which has been shown to activate the RyR1 complex (88, 89). 
In addition, phosphorylation of Ser2843 can enhance RyR1 activity through dissociation of 
FKBP12 from the receptor (29, 90-93). Mass spectrometry experiments of this thesis allowed 
for the identification of the exact amino acids of RyR1 that are susceptible to 3NT and MDA 
modifications. 
Increases in post-translational modifications on RyR1 have been shown to make the channel 
less stable which may result in Ca2+ leak and less Ca2+ release that in turn can contribute to 
muscle weakness (7). For example, increased RyR1 nitrosylation leading to RyR1 channel 
leak has been associated with reduced grip-strength in mdx mice, a mouse-model of 
Duchenne muscular dystrophy (85). In addition, a higher level of nitrosylated RyR1 along 
with increased Ca2+ sparks and decreased muscle force have been found in aged mice as 
compared to young control mice (80). Moreover, increased oxidative stress (3NT, MDA) of 
RyR1 has been linked to decreased muscle force production in RA (2). Thus, although 
associated to muscle weakness in RA, it is not entirely understood how 3NT and MDA 
modifications affect the gating properties of RyR1. In this thesis, we directly measured the 
effects of introducing 3NT and MDA modifications on RyR1 open probability with single 
channel recordings in lipid bilayers.  
1.4 SOURCES & SCAVENGERS OF ROS IN SKELETAL MUSCLE 
Although oxidative stress is associated with RA, it is up until today not clear how arthritis 
affects the sources and scavengers of ROS in skeletal muscle and how that causes oxidative 
stress. Mitochondria, NADPH oxidases (NOX) and nitric oxide synthases (NOS) have all 
been associated with ROS production in RA-induced muscle weakness (19). The scavenging 
of ROS originating from these sources is facilitated by ROS scavengers such as SOD2, 
catalase and GPX1 (37).  
 20 
1.4.1 Mitochondria as a source of ROS 
Mitochondria are organelles that are present in skeletal muscle and are the main producer of 
energy in the form of ATP (94). They consist of an inner and an outer membrane surrounding 
the intermembrane space and mitochondrial matrix (94). The inner membrane holds a lot of 
proteins such as the mitochondrial protein complexes (I, II, III, IV and V), which form an 
electron transport chain to transport protons to the intermembrane space (94). The generated 
proton gradient (protonmotive force) is used by complex V for the synthesis of ATP. During 
electron transport, oxygen is consumed by complex I, III and IV, and therefore these sites in 
the mitochondria are known sources of ROS, especially for O2
•- formation, in skeletal muscle 
(95). The complexes can produce O2
•- through one-electron transfer from a prosthetic group 
of a mitochondrial complex to O2 (96). Complex I and III are considered the two major sites 
of O2
•- production in the mitochondria (Figure. 7) (96, 97). 
Complex I (CI) is the first complex of the electron transport chain (ETC) and transfers 
protons from NADH to the mitochondrial intermembrane space. Oxidation of NADH causes 
electrons to be transferred to co-factor flavine mononucleotide (FMN) of CI which transfers 
the electrons to co-enzyme Q10 (CoQ). O2 is likely to be accessible for FMN and CoQ which 
make these two electron carriers likely to cause O2
•- production (96). Already in 1977 it was 
shown that isolated CI produces O2
•- through fully reduced FMN and the proportion of 
reduced FMN is determined by an increase in [NADH] (98). Therefore, the ratio of ratio 
NADH/ NAD+ may determine the rate of O2
•- by CI. An increase in [NADPH] has been 
hypothesized to be an effect of inhibition of respiration, mitochondrial damage or mutations, 
ischemia, loss of cytochrome c or low ATP demand and consequent low respiration rate (96). 
Other mechanisms of O2
•- production by CI have been described, e.g. O2
•- formation by 
reversed electron transport (RET) (96). RET occurs when electrons reduce the CoQ pool 
which in the presence of a significant protonmotive force transfers electrons back from 
CoQH2 to FMN of CI. The site of CI that produces O2
•- during RET is however still unclear.  
Complex III (CIII) is the third complex of the ETC which receives electrons from CoQH2 
(95). The catalytic subunit of CIII consists of cytochrome b, c and an iron-sulfur center (95). 
There are two interaction sides of CIII for CoQ: the oxidation side (Qo) and reduction side 
(Qi) (95). When Qi is inhibited with antimycin and when supplied with CoQH2, CIII is known 
to produce O2
•- (96). However, O2
•- formation by complex III in physiological conditions is 
supposedly negligible compared to CI (96).   
Mitochondrial dysfunction and altered specific mitochondrial gene expression have been 
associated with arthritis (18, 99, 100). Analysis of multiple microarray gene expression 
studies have indicated a differential expression of nuclear encoded genes of the mitochondrial 
complexes associated with mitochondrial dysfunction in the synovium of RA patients (100). 
Whether these observations are also valid for muscles affected by arthritis and if it leads to 
increased mitochondrial ROS production is not yet fully understood. In this thesis, the ROS 
production by mitochondria was measured in muscles afflicted with arthritis by using 
genetically encoded ROS probes specifically targeted towards the mitochondria. 
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1.4.2 ROS producers NOX2, NOS and PLA2 
The identification of factors that are behind the decreased force production is an ongoing 
process, and other sources of ROS associated with RA-induced muscle weakness, e.g. NOX 
and NOS have previously been reviewed by our group (19). NOX can form O2
•- by 
transferring electrons from NADPH to O2 (101). Seven isoforms of NOX have been 
described of which NOX2 and NOX4 are present in skeletal muscles (101),(102). Other than 
NOX, NOS can produce ROS in skeletal muscle.  NOS are homodimeric enzymes and three 
isoforms have been described; NOS1, NOS2 and NOS3, or also known as neuronal NOS 
(nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS), respectively (103). NOS is 
forming NO, but in circumstances of sub-optimal L-Arginine concentrations, NOS can 
uncouple and cause the release of both NO and O2
•- (103, 104), which can react to form 
ONOO-. Thus, NOS is an inducer of NO, as well as O2
•- and ONOO-.  
Increased levels of nNOS and NOX2 have been observed in muscles from rodent models of 
arthritis (2, 3).  However, up until today the effects of those enzymes in the context of muscle 
weakness arising in RA has not yet been clearly determined. In addition to NOX2 and NOS, 
phospholipase 2 (PLA2) may also contribute to increased ROS production in association with 
arthritis. PLA2 hydrolyze phospholipids to arachidonic acid  (AA) which is the main 
precursor for the formation of MDA both in the enzymatic and non-enzymatic pathway of 
MDA formation (42). Increased skeletal muscle ROS production by PLA2 has been ascribed 
to enhanced mitochondrial ROS production (105) or enhanced lipoxygenase-dependent ROS 
production (106). In the last paper of this thesis, the gene and protein expression for NOX2 
were measured in skeletal muscles affected by arthritis in comparison with healthy control 
muscles. In addition, genetically encoded ROS probes targeted towards NOX2 were used to 
study the NOX2-specific ROS production in muscles affected by arthritis. 
1.4.3 ROS scavengers SOD, catalase and GPX1 
 
The scavenging of ROS in skeletal muscle happens through by a specialized antioxidant 
defense system in order to prevent oxidative damage. The term antioxidant has been defined 
as “any substance that delays or prevents the oxidation of a substrate” and there are both 
biological and dietary antioxidants (e.g. vitamin E, vitamin C and carotenoids) (37). The 
biological antioxidants can subsequently be divided into antioxidant enzymes and non-
enzymatic antioxidants. Further in this thesis, we refer to the biological enzymatic 
antioxidants as ROS scavengers. Superoxide dismutases (SOD), catalase, and glutathione 
peroxidases (GPX) are considered as the primary scavengers of O2
•- in skeletal muscle (37) 
(Figure. 7). Other ROS scavengers in skeletal muscle are thioredoxins (TRX), 
peroxiredoxins (PRX), heme oxygenases (HMOX) and NAD(P)H dehydrogenases 
(NQO)(37, 107).  
There are three different isoforms of SOD (SOD1, SOD2 and SOD3) and they scavenge O2
•- 
to H2O2. All SOD contain a metal ion in its catalytic site for the catalytic breakdown of O2
•-; 
SOD1 carry (Cu) or zinc (Zn); SOD2 carry manganese (Mn) and SOD3 carry copernicium 
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(Cn) or Zn (37, 108). Catalase scavenges H2O2 to H2O plus O2 and contains iron at its active 
site (37, 109). In addition to catalase, GPX is scavenging H2O2 and five different isoforms 
GPX have been described (37). GPX scavenges H2O2 through catalyzation of the reaction of 
glutathione (GSH) with H2O2 to glutathione disulfide (GSSG) and H2O (37).  
Although the specific location of SOD, catalase and GPX have been described, the exact 
subcellular localization in skeletal muscle is still not completely elucidated. Of the isoforms 
of SOD, SOD1 is thought to be localized in the cytosol and mitochondrial intermembrane 
space, SOD2 in the mitochondria and SOD3 is in the extracellular space (37, 108). Catalase, 
is known to be present in the peroxisomes of the skeletal muscles, an organelle that is 
metabolically linked and interacting with the mitochondria (110, 111). Of the five isoforms, 
GPX1 and GPX3 are expressed in all tissues including skeletal muscle, and GPX1 is 
specifically located in the cytosol and mitochondria (37). If the scavengers can change their 
position upon inflammation-induced oxidative stress is not known and whether their 
expression increases at a specific location where increased ROS production may happen is 
neither elucidated. In this thesis we looked at the expression of two of the main scavengers of 
O2
•- and H2O2, i.e. SOD2 and catalase, in skeletal muscle, by super-resolution imaging with 
an airy scan confocal microscope and compared the expression and subcellular localization 
between muscles afflicted with arthritis and healthy muscles.  
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Figure 7. Illustration of mitochondrial ROS production and scavenging. Mitochondrial ROS is 
thought to be mainly produced by complex I and III (CI & CIII). Those can convert oxygen (O2) to 
superoxide (O2•-) either in the mitochondrial matrix or intermembrane space as illustrated above. 
Superoxide is scavenged by SOD1 in the intermembrane space and SOD2 in the mitochondrial matrix 
to hydrogen peroxide (H2O2). H2O2 is subsequently scavenged by GPX in the intermembrane space 
and mitochondrial matrix to water (H2O), or by catalase (thought to be present in the peroxisomes) to 
H2O and O2. 
1.5 COUNTERACTING MUSCLE WEAKNESS IN RA 
The pathogenesis of RA is complex, and it is therefore difficult to find a marker to monitor 
the severity of the disease (15). Instead, the RA disease severity is measured through scoring 
systems that assess several factors such as the number of swollen and tender joints, the 
erythrocyte sedimentation rate, and a questionnaires that aim at measuring a patient’s 
sensation of pain, fatigue, and overall health (15, 112). These scoring systems, e.g. the 
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commonly used disease activity score (DAS), can classify the state of RA in: remission, low 
disease activity, moderate disease activity and high disease activity (15). RA is currently 
treated through a so called “treat-to-target” approach. That means that the aim of the 
treatment of RA is disease remission which aims to improve the patient’s physical function, 
prevents the progression of joint damage, improves quality of life and ability to work and 
reduces comorbidity risks (15). The definitions of disease remission have been set in Europe 
and America, respectively, by the European League Against Rheumatoid Arthritis (EULAR) 
and American College of Rheumatology (ACR)(113, 114). Upon recommendation of 
EULAR, the current first line treatment of RA are short-term glucocorticoids and disease-
modifying anti-rheumatic drugs (DMARDs) (113). DMARDs can be divided in conventional 
DMARDs (e.g. methotrexate and leflunomide) with a broad immunosuppressive activity and 
biological DMARDs (e.g. adalimumab and sarilumab) which target a specific 
proinflammatory protein such as TNF- or IL-6 (15, 114). Current treatment options are 
efficient in retaining the patients in a state of low activity. However, despite better treatment 
options that keeps the disease in a state of low inflammation and low disease activity, patients 
with RA still suffer from deteriorated physical function, including muscle weakness. This 
indicates that muscle dysfunction is a complication that cannot be counteracted by anti-
inflammatory medication alone. 
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2 AIMS 
  
  27 
The overall aim of this thesis is to determine the role of oxidative stress in muscle weakness 
associated with rheumatoid arthritis. This is further divided into 4 specific sub-aims: 
1. Elucidate muscle capacity (i.e. specific force production and intracellular Ca2+ handling) in 
skeletal muscles affected by arthritis and compare mouse models with patients with RA. 
2. Define the role of peroxynitrite-induced oxidative stress on Ca2+ release, myofibrillar force 
and actin polymerization.  
3. Identify intrinsic factors underlying decreased force production in skeletal muscle affected 
by arthritis.  
4. Identify sources and scavengers of ROS that contribute to the altered ROS homeostasis in 
skeletal muscle afflicted by arthritis.  
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3 METHODOLOGY 
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3.1 ANIMAL MODEL AND HUMAN SUBJECTS 
3.1.1 Study approval 
All studies with animals were performed in accordance to the Swedish Animal Welfare Act, 
the Swedish Welfare ordinance and applicable regulations and recommendations from the 
Swedish authorities. The studies were approved by the Stockholm North Ethical Committee 
on Animal Experiments (see respective ethical numbers in the different papers). All studies 
with RA patients and healthy control persons were approved by the regional ethical review 
board in Stockholm (2014/ 516-31/2) and were all complied according to the Declaration of 
Helsinki. Both oral and written informed consent were given by the participants prior to 
participation in the study.  
3.1.2 CFA induced arthritis  
Induction of unilateral arthritis was done in C57BL/6JRj (Janvier) mice with Complete 
Freund's Adjuvant (CFA, Chondrex) in either the ankle (5uL at 10ug/ul) or knee joint (10uL 
at 10ug/ul). The mice were anesthetized with isoflurane prior (4% induction, 2.5% 
maintenance) to the intra-articular injection. The mice were monitored daily for their health 
and were housed at the local animal facility with a 12h light-dark cycle and food and water 
were provided ad libitum. The diameter of the knee and ankle joints were measured with a 
caliper every other day and the mice were sacrificed at the end of each experiment (either 24h 
or 2 weeks after induction of arthritis).   
3.1.3 RA patients and healthy control persons 
Eleven patients with RA and eleven healthy control persons participated in the study. All 
patients had seropositive RA according to criteria of the American College of Rheumatology, 
ACR 1987, and were on stable disease modifying anti-rheumatic drugs (DMARDs). Their 
disease activity was determined by calculation of the disease activity score (DAS). More 
detailed information of the RA patients can be found in Supplemental Table 4 of Paper I. The 
healthy control group was age-matched (45-62 years old) and were women without an 
inflammatory disease. All participants were subjected to a biopsy of their quadriceps vastus 
lateralis muscle, a Biodex force measurement of the force in their legs, a CT scan of their legs 
and activity measurement with an accelerometer.  
 
3.2 MEASUREMENTS OF FORCE AND PHYSICAL ACTIVITIY 
3.2.1 Ex vivo force measurements  
Extensor digitorum longus (EDL) muscles were dissected from mice for ex vivo force 
measurements. Muscles were kept in a Tyrode solution (containing in mM: 121 NaCl, 5 KCl, 
1.8 CaCl2, 0.4 NaH2PO4, 0.5 MgCl2, 24 NaHCO3, 0.1 EDTA and 5.5 glucose, gassed with 
95% O2/5% CO2 to achieve a bath pH of 7.4). The muscles were subsequently tied with a silk 
knot around the tendon and placed in an organ bath to a force transducer and adjustable 
 30 
holder (World Precision Instruments). Contractile force was measured at a range of 
frequencies (1-150Hz) through stimulating the muscles with supramaximal pulses after 
stretching the muscles to optimal muscle length L0. Absolute force was calculated through 
conversion of mV to mN. Specific force was calculated by normalizing the absolute force 
with the CSA of the muscle, which was assessed by dividing the muscle mass by the product 
of muscle length and density (1.06 g/ cm3). 
3.2.2 Dissected single FDB fiber force measurements  
Single flexor digitorum brevis (FDB) fibers were obtained by dissection and thereafter 
mounted in a chamber between a force transducer and an adjustable holder, as described in 
Paper I. Briefly, the fibers are constantly super-fused with Tyrode solution (containing in 
mM: 121 NaCl, 5 KCl, 1.8 CaCl2, 0.4 NaH2PO4, 0.5 MgCl2, 24 NaHCO3, 0.1 EDTA and 5.5 
glucose, gassed with 95% O2/5% CO2 to achieve a bath pH of 7.4) and contractile force was 
measured at a range of frequencies (1-150Hz) through stimulating the fiber with 
supramaximal pulses at optimal fiber length. [Ca2+]i was measured with Indo-1 (Thermo 
Fisher Scientific) and mean fluorescence of Indo-1 was measured at rest and during tetanic 
contractions. An intracellular established calibration curve was used to convert mean 
fluorescence to [Ca2+]i (115).  
3.2.3 Myofibrillar force measurements  
Myofibrillar force measurements were performed for Paper I and II. In brief, myofibrils were 
isolated from rabbit psoas muscle as previously described (116-118) and resuspended in rigor 
buffer (containing in mM: 10 imidazole, 100 KCl, 2 MgCl2, 1 EGTA, pH 7.2) or relaxing 
buffer (20 imidazole, 7.2 mM EGTA, 13.74M CaCl2, 5.4 mM MgCl2, 68.7mM KCl, 5.6 mM 
ATP, and 14.4 mM creatine phosphate, pH 7, pCa2+ 9). The myofibrils were then incubated 
in either SIN-1 (Cayman Chemicals) [10mM] 10min at 4 °C or ONOO- (Cayman Chemicals) 
[0.05-2mM] in 0.3M NaOH. The reaction with SIN-1 or ONOO- was terminated through 
exchanging the buffer with new rigor or relaxing buffer without SIN-1 or ONOO-. The 
myofibrils were then mounted to a glass needle and an atomic force cantilever in an 
experimental chamber placed on an inverted microscope. The length of the myofibril 
sarcomere was adjusted to 2.8μm and contraction was induced by adding activation buffer 
(containing in mM: 20 imidazole, 7.2 EGTA, 7 CaCl2, 5.4 MgCl2, 52.3 KCl, 5.7 ATP, 14.4 
creatine phosphate, pH 7, pCa2+ 4.5). The deflection of the cantilever was measured by 
measuring the deflection of the laser light that was shined upon the cantilever. Through the 
known stiffness of the cantilever, the deflection of the light could be translated to force in 
kN/μm2. 
3.2.4 Biodex force measurements 
RA patients and healthy control persons were subjected to Biodex force measurements of the 
force in their legs. The subjects were carefully positioned in the chair of a Biodex System 4 
Pro (Biodex Medical Systems Inc.) and were instructed to perform isolated measurements of 
quadriceps muscle force. The force measurements consisted of 3 repetitions of maximal 
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isometric contractions with the angle of the knee at 120°. The measured peak torque in Nm 
was converted to specific force in kN/m2 by using the defined length of the cantilever in 
which the leg was fixed and the cross-sectional area of the muscle which was obtained 
through a CT-scan of the leg. ImageJ was used to specifically measure the CSA of the 
quadriceps at the intermediate of the femur bone.  
3.2.5 Accelerometry 
All RA patients and healthy control persons were subjected to measurement of their daily 
activity with an accelerometer (GT, ActiGraph). The accelerometer was worn for 7 
consecutive days and the obtained data was analyzed with the Actilife software. All periods 
of >90 minutes of consecutive inactivity were classified as non-worn periods and were 
excluded from the analysis using the algorithm of Choi et al. (119). Thereafter, the total 
activity in minutes was divided by the validated wearing period. The degree of activity was 
categorized according to the validated categorization of Freedson et al. (120).  
3.3 MOLECULAR BIOLOGY 
3.3.1 Purification of SR extracts and single RyR1 channels  
SR extracts were obtained from pooled gastrocnemius muscle from healthy C57BL/6JRj 
mice. The muscles were homogenized in homogenization buffer (containing in mM: 300 
sucrose and 5 imidazole, pH 7.4). The homogenate was centrifuged (20min, 12000 x g, 4 °C) 
and the pellet was resuspended in homogenization buffer and subsequently centrifuged again 
(same time, speed and temperature). The new supernatant was centrifuged in an ultra-
centrifuge (Beckman Optima MAX-XP ultra-centrifuge) at 4 °C for 2h at 43 000 x g. 
Thereafter, the newly formed pellet containing RyR1 enriched SR fractions was resuspended 
in homogenization buffer. The volume of all buffers was kept constant at 10 w/w volume of 
the initial pooled muscle mass. All buffer contained protease inhibitor (containing in mM: 
0.001 leupeptin, 0.001 pepstatin, 1 benzamide and 0.7 PMSF) and phosphatase inhibitor 
(containing in mM: 2 Na3VO4; 5 NaF; 1 β-glycerophosphate). 
3.3.2 Immunoblots  
Muscle tissue was homogenized in homogenization buffer (containing in mM: 10 Tris-
maleate, 100 KCl, 2 MgCl2, 2 EGTA, 2 Na4P2O7, 1 NaVO4, 25 KF, and protease inhibitor 
(Roche, 1 tablet/50 ml), pH 7.4). The homogenate was centrifuged at 4 °C for 10 minutes at 
1000 x g. The supernatant was collected, and the protein concentration was measured with a 
Bradford assay (Biorad). Equal amounts of protein were separated in a gel by electrophoreses 
and transferred onto a PDVF membrane (Immobilon-FL, Milipore). Membranes were 
subsequently incubated with a primary antibody and secondary infrared-labeled antibody (see 
respective papers for antibody details) and washed with tris-buffered saline (TBS-T) 
(containing in mM: 50 Trizma® base, 150 NaCl) + 0.5% Tween (Sigma-Aldrich) in between. 
Immunoreactive bands were read with the LI-COR Odyssey Infrared Imaging System and 
analysis of the intensity of the bands was done with Image J.  
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3.3.3 RNA isolation  
RNA was isolated from 20mg of muscle tissue obtained from interosseous or gastrocnemius 
muscle. This was done by homogenization of the muscles in RLT buffer (Qiagen) with 1% β-
mercaptoethanol (BME) in a bead shaker. The homogenate was incubated with trizol and 
chloroform and centrifuged (10min, 12 000 x g, 4 °C). The aqueous phase was collected and 
incubated with chloroform and centrifuged (10min, 12 000 x g, 4 °C), which was repeated 
twice. After that, the new aqueous phase was collected and set to precipitate with isopropanol 
(Sigma-Aldrich) for 30 minutes at -20 °C. Centrifugation (10min, 12 000 x g, 4 °C) resulted 
in a pellet containing RNA which was then washed twice with ethanol before drying and 
diluting it in nuclease-free water (Thermo Fisher Scientific). The RNA concentration was 
measured with a spectrophotometer (NanoDrop, Thermo Fisher Scientific) after treatment of 
the RNA with Turbo DNase (Thermo Fisher Scientific).  
3.3.4 Reverse transcription  
Reverse transcription with SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific) 
was used to convert RNA to cDNA. Oligo(dt) 20 and 10mM dNTP mix (Thermo Fisher 
Scientific) were added to 600ng RNA, which was then incubated for 5 minutes at 65 °C. The 
reverse transcription reaction was thereafter initiated at 50 °C after adding SuperScript IV and 
1xRT buffer, 5mM MgCl2, 10mM DTT and RNaseOUT (1L20 diluted) (Thermo Fisher 
Scientific). After 50 minutes, the reaction was terminated at 85 °C for 5 minutes and 
subsequently the newly formed cDNA was cooled at 4 °C.  
3.3.5 RT-PCR  
RT-PCR was performed with 1:20 diluted cDNA from the reverse transcription step. The 
reaction mix consisted of iTaq™ Universal SYBR® Green supermix (Biorad) added to the 
cDNA with respective primers of the genes of interest in a 384 well plate. A melt curve 
protocol was applied with a C1000 TouchTM Thermo Cycler (Biorad): 1 cycle 95°C 3 min; 40 
cycles of 95 °C 10 seconds, 1 cycle 60 °C 30 seconds. SYBR® Green fluorescence was 
measured to determine the Cq values of the different genes of interest. RT-PCR data was 
analyzed by normalization towards housekeeping genes HPRT and Rplp0 by using the ΔΔCt 
method. 
3.4 ACTIN POLYMERIZATION AND SINGLE CHANNEL RECORDINGS  
3.4.1 Actin polymerization assay  
Actin polymerization was measured using a pyrenyl-assay (121). G-actin (Cytoskeleton, 
AKL99) was solubilized in G-buffer (containing in mM: 5 Tris-HCl, 0.1 CaCl2, 0.5 ATP, 0.5 
DTT, pH 7.6) and thereafter incubated in SIN-1 [5, 10 or 20mM], 15 min at room 
temperature. Actin concentration was determined by measuring absorbance using the 
excitation coefficient of actin E= 0.63 ml/ mg x cm as previously described (122). Actin [8 
μM] and pyrene-labelled actin [4% of actin concentration] were added to a dark 96 well plate. 
EGTA and MgCl2 [0.2 and 0.05mM respectively] were added to replace actin bound Ca
2+ for 
  33 
Mg2+. Ten minutes later, polymerization of actin was induced, by addition of MgCl2 and KCl 
[1 and 100mM respectively] and the polymerization was followed by excitation at 365 nm 
and emission detection at 410 nm (Fluoroskan II, Labsystems). The steady state fluorescence 
was measured 24h and 48h after induction of polymerization.  
3.4.2 Single RyR1 channel recordings  
Isolated single RyR1 channels from SR fractions, were added to a lipid bilayer that separated 
a cis (cytoplasmic) and a trans (luminal) solution (cis containing in mM: 230 Cesium 
Methanesulfonate (CsMS), 20 CsCl, 1 CaCl2, and 10 TES, pH 7.4; trans containing in mM: 
30 CsMS, 20 CsCl, 1 CaCl2, and 10 TES, pH 7.4). The RyR1 channels were added to the cis 
solution so the cytoplasmic surface faced the cis solution after incorporation in the lipid 
bilayer. The [Cs+] in the trans solution was raised to 250mM by addition of 200mM CsMS. 
To achieve a final free [Ca2+], 2mM ATP and ~1.32mM 1,2-bis (o-109 aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid (BAPTA) were added. Recordings of the open probability (Po) of the 
channel were done by measuring the current flow through the channel at +40 and -40 mV at 
23°C. These voltages ensured a large current flow through the channel. The data obtained 
was analyzed using the Channel 2 program (developed by P.W. Gage and M. Smith, John 
Curtin School of Medical Research, Canberra, Australia). All data was sampled at 5kHz, 
filtered at 1 kHz and the baseline noise was excluded which was set as ~20% of the 
maximum single-channel conductance measured as Po.  
3.5 ANALYTICAL ANALYSIS OF PROTEIN BIOLOGY 
3.5.1 Mass spectrometry  
With mass spectrometry the oxidative post-translational modification (oxPTMs) were 
identified on RyR1 and actin. Specifically on: (i) actin from myofibrils incubated in SIN-1, 
(ii) purified actin (Cytoskeleton AKL99) incubated in SIN-1, (iii) actin from skeletal muscle 
from mice with CFA-induced arthritis, (iv) actin from skeletal muscle from patients with RA 
and (v) RyR1 from SR-extracts incubated in SIN-1. The protein samples were digested with 
trypsin and subsequently cleaned in a HyperSep plate and dried in a speedvac centrifugal 
evaporator. The trypsin-digested peptides were separated by chromatography and ionized by 
electrospray in an Orbitrap QExactive Plus mass spectrometer (Thermo Fisher Scientific). 
The survey MS spectrum was acquired at a resolution of 60.000 (m/z range 200-2000). The 
MS/MS data were extracted with RawtoMGF software and analyzed with Mascot (Matrix 
Science, version 2.5.1) and X!Tandem (thegpm.org; version CYCLONE 2010.12.01.1). 
Variable post-translational modifications of amino acids were set as tyrosine nitrations, 
cysteine nitrosylations and MDA modifications alongside fixed modifications as cysteine 
carbamidomethylations that were introduced as a result of sample preparation. The protein 
prophet algorithm (123) was used to assign protein probabilities and Scaffold (version 
Scaffold_4.4.5, Proteome Software Inc.) was used to validate the identified MS/MS-based 
peptides and post-translational modifications.  
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3.5.2 Chimera 3D protein modeling  
All validated variable post-translational modifications on actin and RyR1 were visualized in 
the 3-dimensional crystal structure of either actin or RyR1 (see the respective papers for the 
PDBe protein codes and references). Prior to visualization, ClustalW (124) was used to 
investigate the amino acid sequence homology between rabbit, human and mouse actin and 
between rabbit and mouse RyR1. The UCSF-Chimera software (ref 25 paper III) was used to 
find the location in the 3-dimensional model of actin or RyR1. The modifications were 
subsequently presented as spheres and annotated with their one-letter code specifier in the 
respective figures of paper I and III.  
3.5.3 Molecular dynamic simulations  
Molecular dynamic simulations were performed with Gromacs (simulation package 5.1.2.) 
(125) on the 3.3Å structure of rabbit skeletal muscle F-actin, PDBe 2ZWH, which includes 
all amino acid residues of actin and has previously been used in molecular dynamic-
simulation studies (126-128).The F-actin structure was solvated in a truncated dodecahedron 
box for minimal distance between any protein atom and 52 K+ and 39 Cl- ions were added for 
neutralizing the protein and mimicking an ionic strength of 0.15M. A force field was applied 
(129) for all atoms except Ca2+, K+ and Cl-. The LINCS (130) algorithm was used to 
constrain the length of bonds during the molecular dynamic runs. Other parameters were set 
such as temperature (300K), pressure (coupled to an external bath with the Parrinello-
Rahman algorithm (131) and van der Waals forces (truncated at 1.0nm). The long-range 
electrostatic forces were treated using the particle mesh Ewald method (132, 133). Four 
molecular dynamic simulation replicates of each 100ns were performed and the analysis of 
those was performed with use of Gromacs.  
3.6  MEASUREMENTS OF ROS SOURCES AND ROS SCAVENGERS 
3.6.1 Electroporation of roGFP for live cell imaging of ROS  
Reduction-oxidation sensitive genetically encoded green fluorescent protein (roGFP) plasmids 
targeted to the mitochondria (mito-ro1GFP) (134) or NOX2 (p47phox-roGFP2) (135) were 
amplified in E. coli bacterium at 37°C. The plasmid-DNA was purified after 24h with a maxi-
prep E.Z.N.A.® kit (Omega Bio-tek) according to manufacturer’s instructions. Hyaluronidase 
(10u, 2g/l) was injected in the footpads of the mice 1h prior to plasmid electroporation.  The 
roGFP plasmids were injected in the footpad of C57BL/6JRj mice (Janvier). Electroporation in 
the flexor digitorum brevis muscle (FDB) happened through giving 20 electric pulses of 1Hz for 
20ms at 100V to the plasmid-injected footpad of the mouse. After electroporation, the mice were 
injected with TEMGESIC (35 l/ mL PBS) to reduce pain caused by the electroporation protocol. 
3.6.2 Single muscle fiber dissociation  
FDB muscles were dissected in Tyrode (containing in mM: 121 NaCl, 5 KCl, 1.8 CaCl2, 0.4 
NaH2PO4, 0.5 MgCl2, 24 NaHCO3, 0.1 EDTA, and 142 5.5 glucose) from mice with CFA-
induced arthritis in the ankle, 24h or 2 weeks after induction of arthritis. The muscles were then 
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incubated in collagenase type I (3 mg/ml in DMEM+ 10% FBS) in an incubator (37°C, 5% CO2) 
for 2h. Thereafter the dissociated muscles were gently pipetted to separate them and then 
transferred into fresh DMEM and cultured on 2% laminin-coated plates (MatTek) for roGFP live 
cell imaging or on a Nunc™ Lab-Tek™ chambered cover-glasses for immunofluorescence 
imaging of ROS scavengers.   
3.6.3 RoGFP live cell imaging for ROS production  
Live ROS production was measured in dissociated FDB fibers expressing mito-ro1GFP or 
p47phox-roGFP2 in muscle afflicted with inflammation (24h after induction of arthritis with 
CFA) or control muscle (injections were done as described above). A three steps protocol was 
followed whereby the mito-ro1GFP and p47phox-roGFp2 probes were excited at 488nm and 
emitted light was collected at >500 nm. In the first step the fibers were perfused with Tyrode 
(containing in mM: 121 NaCl, 5 KCl, 1.8 CaCl2, 0.4 NaH2PO4, 0.5 MgCl2, 24 NaHCO3, 0.1 
EDTA, and 142 5.5 glucose) in order to capture baseline fluorescent emitted light. Tyrode was 
then exchange for Tyrode with DTT (1mM) to reduce the cellular environment and thereby detect 
the maximum fluorescence (Fmax). Last, Tyrode with DTT was exchanged for fresh Tyrode 
without DTT, to capture ROS production for a minimum of 20 minutes. All imaging was 
performed with a confocal imaging microscope (Zeiss LSM700, 40x zoom, water-based lens). 
The analysis of fluorescent intensity of each cycle was performed in ImageJ and normalized to 
Fmax. 
3.6.4 Immunofluorescent imaging of ROS scavengers  
Dissociated FDB fibers were fixed with paraformaldehyde for 20 min at room temperature and 
subsequently washed with PBS and blocked for unspecific antibody binding with goat serum. 
Thereafter, the fibers were stained with primary antibodies for ROS scavengers SOD2 
(Ab13533, Abcam), catalase (Ab16731, Abcam) and α-151 actinin (A7811, Sigma) and 
incubated with secondary antibodies (anti-153 rabbit A11035, anti-goat, A32816, anti-mouse, 
A11029, Thermofisher). Images were captured with a super-resolution Zeiss LSM800 Airyscan 
microscope (resolution: 2.997 pixels per micron; 40x zoom) and analyzed with ImageJ.  
3.6.5 Catalase activity assay  
The enzymatic activity of catalase was measured with a colorimetric assay (ab83464, 
Abcam) in homogenized interosseous muscle from mice with CFA-induced arthritis. The 
interosseous muscle from both the arthritic and control leg were homogenized in 20 weight/ 
volume catalase assay buffer. Protein concentration in each sample was measured with a 
Bradford (Biorad) assay. Equal amounts of protein were loaded in a 96-well plate and 
incubated with H2O2 for 30 minutes at 35 °C. The H2O2-sensitive dye OxiRed (Abcam) was 
added after the incubation period and the absorbance was measured at 570nm. The amount of 
H2O2 converted by catalase over time was calculated by means of a standard curve.  
3.7 STATISTICS 
The data of this thesis is analyzed through the following statistical approach.  Mean data is 
presented ± SEM. For all statistical analysis, first the normal distribution was tested with a 
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Shapiro-Wilk and equal-variance was tested with a Brown-Forsythe test. If the data set 
contained no equal variances, then a Mann-Whitney test was used. A data set that passed the 
Shapiro-Wilk test (P> 0.05) and Brown-Forsythe test (P> 0.05), was compared using an 
unpaired two-tailed Student’s t-test.  Difference among more than 2 groups were analyzed with 
an ANOVA test with a Tukey’s honest significant difference post hoc test, followed by a 
Bonferroni’s multiple comparison test. Linear regression analysis was used to determine the 
degree of linear correlation between two seemingly linear dependent values. In all analysis, a 
P value less than 0.05 was considered significant (* P < 0.05; ** P < 0.01; *** P<0.001).   The 
analysis was performed using Sigma plot 13.0 (Systat Software) or Prism 7 (GraphPad). 
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4 RESULTS AND DISCUSSION 
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4.1 OXIDATIVE MODIFICATIONS ON ACTIN PROMOTE MUSCLE WEAKNESS 
IN RA (PAPER I & II) 
4.1.1 Decreased force of muscle from mice with arthritis 
In order to understand how RA causes muscle weakness, we investigated the effects of 
arthritis on the skeletal muscle performances with taking in consideration the muscle size. 
Arthritis was induced by unilateral intra-articular injection of Complete Freund’s adjuvant in 
the knee or ankle joint of C57BL/6JRj mice. At peak inflammation, i.e. 2 weeks after 
induction of arthritis, the diameter of the respective injected ankle or knee was significantly 
bigger than in healthy control mice (paper I, suppl. fig. 1A &B). At this time point, the 
muscle force was measured ex vivo, in both whole muscles and single muscle fibers of the 
arthritic leg and the healthy control leg. A significant decreased force was observed in both 
whole muscle and single muscle fibers affected by arthritis compared to healthy control (Ctrl) 
muscles (paper I, fig. 1F & suppl. fig. 1C&D). The cross-sectional area (CSA) of the EDL 
and FDB fibers was however not significantly different between healthy control muscles and 
muscles from the arthritis leg (paper I, fig. 1 G & suppl. fig. 1E&F). In contrast to other 
models of arthritis such as collagen-induced arthritis (CIA)(2), mice with CFA-induced 
arthritis develop an inflammation that is primarily localized to the local area of the injection. 
Indeed, unilateral induction of arthritis with CFA, did not affect the force in the muscles of 
the contralateral leg. The force production of these muscles was namely not significantly 
different from muscles from wild-type C57BL/6JRj mice (paper I, suppl. fig. 1C). 
4.1.2 Altered Ca2+ handling of muscles from mice with arthritis 
As described in the introduction, section 1.2.3., intrinsic muscle dysfunction can be an effect 
of altered Ca2+ handling (19). Ca2+ release from the SR through RyR1 is necessary to uncover 
the myosin binding sites on actin. Subsequently, Ca2+ enables actin-myosin cross bridge 
formation, hence a higher [Ca2+]i results in increased myofibrillar force until saturation of 
[Ca2+]i  and saturation in the number of force generating actin-myosin cross bridges (31, 97). 
In mice with CFA-induced arthritis in the ankle, the tetanic [Ca2+]i of the muscle fibers from 
the arthritic leg, did not significantly differ from the tetanic [Ca2+]i in muscle fibers of the 
control leg at stimulation frequencies 1 till 150 Hz although a significantly declined force 
(paper I, fig. 1H-I). Moreover, the Ca50, i.e. [Ca
2+]i at 50% of peak power (Pmax), was neither 
significantly different between the muscle fibers affected by arthritis and the control muscle 
fibers. These results indicated that Ca2+ release and myofibrillar Ca2+ sensitivity was not 
affected by CFA-induced arthritis. To effectively release all Ca2+ stored in the SR, skeletal 
muscle fibers can be incubated with caffeine (5mM) and stimulated at high-stimulation 
frequency (120Hz) (71). Indeed, Ca2+ release was enhanced by caffeine at 120Hz stimulation 
in muscle fibers affected by CFA-induced arthritis and healthy control fibers yet did not 
significantly differ between the arthritis affected muscles and healthy control muscles and  
neither did it improve force production (paper I, fig. 1J-K). These results showed that the 
tetanic force at 120Hz of the healthy control muscle fibers after caffeine application was close 
to maximum. However, in the arthritis affected muscle fibers, the force did not improve to the 
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level of the control muscles, despite caffeine induced Ca2+ release that would enable 
maximum force production at 120Hz. These results suggest that in mice with CFA-induced 
arthritis, the lower force in muscles affected by arthritis is caused by a decreased ability of 
actin and myosin to generate myofibrillar force rather than the other two hypothesized causes 
of intrinsic muscle weakness, i.e. decreased Ca2+ release or decreased myofibrillar Ca2+ 
sensitivity. 
4.1.3 Decreased force of muscles from patients with RA 
Previous research of muscle strength in RA patients, e.g. by Ekdahl and Broman, have not 
normalized muscle force towards the muscle size (6). However, already in 1994 Helliwell 
and Jackson reported that only ~40% of the decreased muscle strength can be explained by a 
decrease in muscle size (12). It may be to notion that, in addition to measuring absolute force, 
measuring muscle force in RA patients and normalizing muscle force to muscle size, gives 
extra information how muscle weakness persists in RA patients. We have therefore assessed 
the physical capacity of RA patients through measurements of the force produced by the 
thigh muscles (quadriceps femoris) and normalized it to the size of the muscle which was 
measured by a CT-scan. The RA patients included in this study had a moderate state of the 
disease (average DAS of 3.3 ± 0.4) and all presented arthritis in the lower extremities (paper 
I, suppl. table 4). In addition, all patients were being treated with DMARDs that target pro-
inflammatory signaling such as TNFα or a general immunosuppressant. In the RA patients of 
this study, the specific force, i.e. normalized to CSA, of quadriceps femoris was significantly 
lower than the specific force of age- and weight-matched healthy women (paper I, fig. 5 B). 
The CSA of the quadriceps muscle of the RA patients was not significantly different than the 
CSA of the quadriceps muscle of the healthy control subjects (paper I, fig. 5D). Thus, 
although the RA patients were on stable DMARD therapy, the results show that RA patients 
present muscle weakness which cannot be explained by altered muscle size, comparable to 
the observed results in rodent models of arthritis and the CFA mice of our study. 
Inflammation-induced pain may be a contributing factor to a sedentary behavior in RA 
patients and which could contribute to reduced muscle performance. We investigated if the 
decrease in force could be linked to a lower physical activity in RA patients than in healthy 
control persons. However, accelerometry measurements showed no difference in daily 
physical activity or degree of physical activity between the RA patients and the healthy 
control persons (paper I, fig. 5D-E).  In fact, it is possible that the previous resistance for RA 
patients to perform physical activity have been associated with a lack of education and 
information about the benefits of physical activity and insufficient awareness among 
rheumatologists, rather than an increased perception of pain by the RA patient (136). 
Moreover, patients with increased physical activity have a decreased the perception of pain 
and fatigue (137). Altogether, this supports the observed results that muscle weakness in RA 
patients cannot solely be explained by a decrease in muscle mass or that physical inactivity 
contributes to the muscle weakness of the patients of our study.  
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Although the muscle mass did not appear to different in the RA patients compared to healthy 
control persons, the muscle quality may have changed without a change in muscle mass (e.g. 
increased muscle fibrosis). Muscle fibrosis is defined as excessive accumulation of extra 
cellular matrix components, especially collagens, in skeletal muscles (138). Thus, fibrosis 
may be a contributing factor to the observed decreased muscle strength in RA patients. 
However, it was not studied in detail in paper I, but should be paid attention in future studies. 
Nevertheless, the data from paper I and previous studies infer that an intrinsic muscle 
dysfunction contributes to muscle weakness in RA. Intrinsic muscle dysfunction is associated 
with oxidative stress not only in RA (2, 3, 19), but also in sepsis (8, 57, 117), muscle 
dystrophy (139, 140), malignant hyperthermia (45), aging (80), heart failure and stroke (141, 
142), ventilatory-induced diaphragm dysfunction (143, 144) and cancer (7). As a matter of 
fact, in the mice with CFA-induced arthritis from this study, a significantly higher level of 
3NT oxPTMs was observed on muscle proteins in the arthritis affected muscles compared to 
the control muscles (paper I, fig. 1B-E). Therefore, the functional effects of oxPTMs on 
myofibrillar force, actin polymerization and RyR1 gating were studied.  
4.1.4 Declined myofibrillar force 
The effects of oxPTMs on myofibrillar force were assessed with atomic force cantilever 
experiments. Oxidative 3NT modifications were introduced on myofibrils with ONOO- or 
with the ONOO- donor SIN-1. Myofibrillar force was significantly reduced in myofibrils that 
were incubated in ONOO- and SIN-1 compared to control conditions (paper II, fig. 1 & 2). 
DTT reduces cysteine nitrosylations that can be introduced by SIN-1. Myofibrils incubated in 
SIN-1 in the presence of DTT, also presented a significant reduction in force compared to 
control myofibrils (paper I, fig. 2A-C). These results thereby showed that ONOO--induced 
modifications on myofibrils, such as 3NT (paper I, fig. 2D), can have direct negative effects 
on muscle force production. The isometric myofibrillar force of a myofibril is dependent on 
the actin-myosin cross bridge kinetics (34). The relationship between isometric myofibrillar 
force an actin-myosin cross bridge kinetics can be described as follows: 
𝐹 =  𝑛𝐶𝐵𝐹𝐶𝐵
𝑓𝑎𝑝𝑝
𝑓𝑎𝑝𝑝 + 𝑔𝑎𝑝𝑝
 
Herein is, F the isometric force of a myofibril (i.e. myofibrillar force), nCB the number of 
actin-myosin cross bridges, FCB the force per cross bridge, fapp the rate of cross bridge 
attachment and gapp the rate of cross-bridge detachment (34). Furthermore:  
𝑓𝑎𝑝𝑝
𝑓𝑎𝑝𝑝 + 𝑔𝑎𝑝𝑝
=
𝑘𝑇𝑟 − 𝑘𝐿𝐼𝑁
𝑘𝑇𝑟
 
The force (F) parameter can be measured with a regular myofibrillar force measurement. On 
the other hand, kTr can be measured with atomic force cantilevers during a so called 
“myofibrillar force redevelopment experiment”. The rate of force redevelopment is kTr. In 
such an experiment, a myofibril is shortened with 15% of the initial myofibril length during 
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steady state activation at pCa 4.5. Then the myofibril is let to redevelop force until steady 
state, followed by relaxation of the fiber at pCa 9.0.  The parameter kLIN is the rate of slow 
(linear) relaxation of a myofibril. There are two phases of myofibrillar relaxation after 
decreasing free [Ca2+]: (i) an initial slow relaxation phase where myofibrillar force declines 
while sarcomeres remain isometric and (ii) a fast relaxation phase where myofibrillar force 
declines while longitudinal movements within the sarcomere occur. In addition to F and kTr, 
kLIN can also be measured with atomic force cantilevers. This is possible after deactivation of 
the myofibril by lowering free [Ca2+] (paper II, fig. 5B). Myofibrillar force measurements in 
combination with a myofibrillar force redevelopment experiments can thus provide detailed 
information about how oxPTMs can affect actin-myosin cross bridge kinetics.  
In myofibrils incubated with ONOO- or SIN-1, no change was observed in kTr (paper II, fig. 
3E). On the other hand, kLIN was significantly increased in myofibrils incubated in SIN-1 
compared to control conditions (paper II, fig. 6A). Because kTr was not changed and kLIN 
was increased in myofibrils carrying oxPTMs, the ratio  
𝑘𝑇𝑟− 𝑘𝐿𝐼𝑁
𝑘𝑇𝑟
 , and thus 
𝑓𝑎𝑝𝑝
𝑓𝑎𝑝𝑝+𝑔𝑎𝑝𝑝
 , 
decreases compared to control myofibrils (paper II, table I). Moreover, the decrease in 
𝑓𝑎𝑝𝑝
𝑓𝑎𝑝𝑝+𝑔𝑎𝑝𝑝
 is of similar magnitude as the decrease in myofibrillar force (i.e. ~55%) (paper II, 
table I). These results suggest that a decreased myofibrillar force due to oxPTMs is likely 
attributed to an increase in kLIN. The properties of kLIN predominantly reflect a transition of 
actin-myosin cross bridges from a force generating state to a non-force generating state (144-
146).  
Together these results show that myofibrils carrying 3NT modifications produce less force 
which is likely caused by a decreased capacity of actin and myosin to form force generating 
cross-bridges. 
4.1.5 Compromised actin polymerization 
Actin forms the centrally located structure of the thin filaments of myofibrils. We 
investigated the effects of oxPTMs on actin polymerization by incubating G-actin with SIN-1 
and measuring actin polymerization with an actin polymerization assay (paper I, fig. 2). 
Actin polymerization was initiated through increasing the [Mg2+] (allowing for exchange of 
Ca2+ to Mg2+ bound to G-actin, which induces polymerization in vitro) under conditions with 
DTT. The polymerization rate was significantly lower for actin carrying oxPTMs introduced 
by SIN-1 than for unmodified actin (paper I, fig. 2). These results agree with previous 
observed finding from Clements et al. showing that the rate of actin polymerization declines 
after incubation of actin with the ONOO- donor SIN-1 (148). Moreover, we showed that the 
steady state polymerization level, measured 24h and 48h after initiation of polymerization, 
was significantly decreased by SIN-1. Altogether, this shows that G-actin carrying oxPTMs 
may thus still be able to form F-actin filaments however the oxPTMs compromise the 
stability of the F-actin filament. Moreover, F-actin filaments with G-actin monomers 
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carrying oxPTMs may be sterically hindered and hence cause an impaired ability of actin to 
bind with myosin and thereby impair myofibrillar force. 
4.1.6 3NT and MDA modifications on actin  
To further elucidate how oxPTMs on actin can cause decreased actin polymerization and 
decreased force production we used mass spectrometry to identify the modified amino-acid 
residues carrying an oxPTM for actin from myofibrils and monomeric G-actin incubated in 
SIN-1 (paper I). It is important to note that the amino acid sequence of skeletal muscle actin, 
(i.e. -actin) is conserved in human, mouse and rabbit (paper I, supplementary table 2). 
This has made it possible to identify the location of all 23 modified amino acid residues of 
actin from SIN-1 incubated myofibrils (n=3) and monomeric G-actin (n=3) and compare 
them with those modified in weakened skeletal muscles of mice with CFA-induced arthritis 
(n=3) (paper I, fig. 3B-D & suppl. table 1), as well as the patients with RA. Two types of 
oxPTMs were identified on actin with mass spectrometry: 3NT and MDA. The location of 
the amino acids carrying a 3NT or MDA modification, were visualized in the crystal structure 
of ATP-bound -actin (65) (paper I, fig. 3). Intriguingly, the modified amino acids of actin 
were at the exact same location or close to each other in the actin from mice with arthritis 
and the SIN-1 treated actin samples. Therefore, we have called these locations “hotspots” of 
oxidative modifications, as these regions of the conserved actin structure appeared to be 
specifically sensitive to oxidative stress (paper I, fig. 4A-C). The first hotspot was located in 
subdomain 1 (SD1) and carried oxidative modified H101/MDA, Q360/MDA and Y362/3NT 
(paper I, fig. 4A). The second hotspot of oxidative modifications was around the flexible D-
loop of actin in SD2, containing H40/MDA, Q41/MDA and Y53/3NT (paper I, fig. 4B). The 
D-loop is known to change confirmation upon ATP hydrolysis and plays an important role in 
the interaction of actin with myosin (64, 70). In addition, the D-loop is involved in 
longitudinal interactions within the F-actin filament (26, 149). Moreover, residue Y53 has 
previously been shown susceptible to ONOO- -induced modification(150) and 
phosphorylation of this residue can cause slower actin polymerization and impaired actin 
filament stability (151-153). These results indicate that oxPTMs of hotspot 2 play a critical 
role with regards to decreased myofibrillar force and actin polymerization. The third hotspot 
was in SD3 and the observed oxPTMs were Y294/3NT, N296/MDA and N297/MDA (paper 
I, fig. 4C). These residues were found modified consistently at the same location in actin 
from mice with arthritis and the SIN-1 modified actin samples which stresses the conserved 
nature of actin.  
4.1.7 3NT and MDA modifications on actin from RA patients  
To see if the previous results also apply for patients with RA, we isolated actin from skeletal 
muscle biopsies from RA patients and identified the oxidative modifications with mass 
spectrometry. Indeed, oxPTMs were found in the oxidative hotspots of actin from the 
quadriceps muscles of RA patients (n=3) (paper I, fig. 5G-I). More specifically, a total of 11 
consistent oxPTMS were found in subdomain (SD) 1, 2, 3 and 4 (paper I, fig. 5F) (SD1: 
H87/MDA, H101/MDA, and Q360/MDA; in SD2: H40/MDA, Q41/MDA, and Q59/MDA; 
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in SD3: H275/MDA, Y294/3NT, and N297/MDA; and in SD4: Y218/3NT and 
Q246/MDA). Molecular dynamic simulations were performed on the structural details of F-
actin with particular regards to the identified oxPTMs in actin from patients with RA. This 
was done to investigate if the oxPTMs of the 3 hotspots in actin are indeed important for 
actin-myosin cross bridge formation and intra-actin filament connections. We looked at the 
root mean square fluctuations (RMSF), the solvent-accessible surface area (SASA), the 
number of H-bonds and the number of contacts of the oxPTMs. The root mean square 
fluctuations (RMSF) were assessed to study the flexibility of the different subdomains of 
actin. The highest flexible regions were found around MDA modified residues H40 and Q41 
of hotspot 2 in SD2 of actin (paper I, fig. 6a). In this part of actin, the D-loop is located 
(residues 38-53). This region of actin also had the highest solvent accessibility, SASA (paper 
I, fig. 6b). Introduction of oxPTMs is a non-enzymatic mechanism and there is currently no 
consensus about the selectivity of the reaction. However, it is thought that the presence of 
nearby charged amino acids, i.e. Arginine (R), Lysine (K), Aspartic Acid (D), Glutamic Acid 
(E) or Histidine (H), provides a favorable environment for the introduction of oxPTMs (154-
156). Indeed, in oxidative modified actin, the observed modifications of the residues in all the 
oxidative hotspots were located near charged amino acids (paper I, suppl. fig. 3). Moreover, 
due to the short half-life of ROS such as ONOO-, ~5-20 ms and O2
-•, ~1 s, the amino acids 
of actin that are susceptible to oxPTMs need to be close and accessible to the site of ROS 
(154, 157), and a high SASA could indeed allow this to be the case. In addition, also Q360 of 
hotspot 1 had a solvent accessibility similar to that of H40 and Q41 (paper I, fig. 6b). Q360 
is located at the outer surface of the actin filament where addition of a covalently bound 
MDA adduct is likely to impose contacts of actin with other proteins. The modifications in 
hotspot 3, i.e. Y294/3NT and N297/MDA, were, intriguingly, located in regions with low 
flexibility and low solvent accessibility. We are unaware how these residues could have been 
accessible for modifications but Radi et. al. imply that local changes in the microenvironment 
can enhance the capacity of the residues to become modified independent of SASA, but the 
molecular details are unclear (43). Nevertheless, Y294 and N297 are proximal to a tight 
electrostatic network of the D-loop in the adjacent subdomain formed by H173, D286 and 
E270 (68). Modifications of Y294 and N297 may therefore result in disruption of the 
longitudinal intramolecular interactions of F-actin and can thereby cause instable F-actin 
filaments. Indeed, Y294 and N297 were those residues that were observed with the highest 
number contacts between non-hydrogen atoms separated by less than 4Å. In fact, all residues 
found modified in the 3 different hotspots had between 35 and 95 contacts (paper I, fig. 6e).  
The results of the molecular dynamic simulations confirm that the modified residues in the 
hotspots in actin are residues important for actin filament stability and myosin interaction. 
Intriguingly, these hotspots were identified in all our experimental settings, i.e. in actin from 
weakened skeletal muscle from mice with arthritis, patients with RA, actin monomers with 
impaired polymerization abilities and weakened myofibrils with oxPTMs. The results 
together, show that oxPTMs in the oxidative hotspots of actin contributes to muscle weakness 
in mice with arthritis and patients with RA.  
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4.2 OXIDATIVE MODIFICATIONS INCREASE THE OPEN PROBABILITY OF 
RYR1 WHICH IS ASSOCIATED WITH RA-INDUCED MUSCLE WEAKNESS 
(PAPER III) 
4.2.1 Increased RyR1 open probability 
RyR1-mediated Ca2+ release from the SR is a tightly controlled process which enables muscle 
contraction (3, 25). Post-translational modifications can affect the function of the RyR1 
complex. The RyR1 complex is known to be sensitive to redox modifications such as 
nitrosylation (88, 89), carbonylation (DNP) (45), MDA adducts (158, 159) and 3NT 
modifications (2). Well-studied post-translation modifications on RyR1 that activate the 
channel, are nitrosylation of cysteine residue 3635 (Cys3635) and phosphorylation of serine 
2843 of RyR1 (S2843) (73). Altered RyR1 activity by redox modifications is known to 
contribute to hyperthermia crisis in environmental heat stress and malignant hyperthermia 
(160) and is associated with muscle weakness in dystrophy (140), aging (80) and breast 
cancer (7). In mice with arthritis, increased levels of 3NT modifications have been found on 
the RyR1-DHPR super-complex which were associated with altered Ca2+ release and muscle 
weakness (2). We investigated if introducing 3NT modifications with the ONOO- donor SIN-
1, would affect the open probability of RyR1 channels (paper III). SIN-1 significantly 
increased the level of 3NT modifications on RyR1 (paper III, fig. 1A). The open probability 
(Po) of RyR1 incubated in SIN-1, was significantly higher (3-fold) than the control condition 
(vehicle) (paper III, fig. 1A&B). SIN-1 is donating NO and O2
-• to produce ONOO-, hence 
it can also lead to nitrosylation of RyR1 (56). To diminish the effect of cysteine 
nitrosylations, Po was also measured of RyR1 incubated in SIN-1 in the presence of DTT. 
RyR1 incubated in SIN-1 with DTT had a lower open probability than RyR1 incubated in 
SIN-1 without DTT, however Po was still significantly higher than the control conditions 
(paper III, fig. 1C-D). The effect of SIN-1 on RyR1 Po was dose dependent, where Po 
increased by ~30% with increasing SIN-1 concentration (0.2mM vs. 1mM SIN-1) (paper III, 
fig. 1E). Since the activity of RyR1 is depended on [Ca2+] (enhanced activation by low 
[Ca2+]cyt, i.e. nM compared to µM, (161, 162)), we also investigated if the effect of SIN-1 on 
the Po of RyR1 was dependent on [Ca
2+]. However, there appears to be a weak, if any, Ca2+ 
dependence as SIN-1 increased Po to a similar extent at 1nM and 100nM [Ca
2+] (paper III, 
fig. 1F).  
4.2.2 3NT and MDA modifications on RyR1 
Several studies have shown that PTMs on RyR1 are associated with increased channel Po, 
FKBP12 dissociation and SR Ca2+ leak (7, 29, 83, 84, 140). PTMs on RyR1 are often studied 
by immunoblotting with antibodies that detect the total amount of PTMs. On the other hand, 
mass spectrometry can detect the exact amino acids that are modified. The importance of 
identifying the exact modified residues becomes clear from studies that show that specific 
amino acid residues modifications of RyR1 are leading to altered gating properties of RyR1, 
i.e. Cys3635(88) and Ser2843(90, 92).  
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During sample preparation for mass spectrometry, DTT was used to reduce any cysteine 
nitrosylations introduced by SIN-1. A total of thirty oxPTMs were found on RyR1 incubated 
with SIN-1, being either 3NT (NO2; +46 Da) or MDA-adducts (C3H3O; +54 Da) on basic 
amino acids (paper III, fig. 2A). Of those thirty, the location of 16 residues could be 
identified in the cytosolic shell and 8 in the core of the 3-dimensional crystal structure of 
RyR1 (PDBe: 5T15(74)) (paper III, fig. 2A-C). One RyR1 monomer consists of 5035 amino 
acid residues and there is currently no consensus regarding the selectivity of oxidative 
modifications. However, as mentioned the presence of nearby charged amino acids, provide 
supposedly a favorable environment for the introduction of oxPTMs (154-156). This agrees 
with the observed result that 23 out of 30 modifications were indeed flanked by charged 
amino acids (paper III, suppl. table 1). 
In RyR1 incubated in SIN-1, the cytosolic shell contained two modifications in the N-
terminal domain (NTD), i.e. N84/MDA and H379/MDA (paper III, fig. 3B). The NTD of 
RyR1 plays an important role in domain-domain interaction and multiple genetic mutations in 
NTD have been identified that underlie malignant hyperthermia, central core disease and 
multi-minicore disease (163). Interestingly H379/MDA is closely located to H383 which is a 
well-known disease mutation site (163).  
A second cluster of modifications in the cytosolic shell, was found in the RyR repeat domains 
1&2 (RY1&2) (paper III, fig. 3C): Y893/3NT, Y920/3NT, Q981/MDA and N991/MDA. In 
addition to RY1&2, oxPTMs were also found in the RY3&4 domain (paper III, fig. 3D): 
Y2855/3NT, Y2908/3NT, Q2931/MDA and Y2935/3NT. The four RyR repeats interact 
within the 3-dimensional structure, RY1&2 from one RyR1 monomer interacts with RY3&4 
of the adjacent RyR1 monomer (paper III, suppl. fig.1). The modifications found in these 
domains may therefore disturb the intra-protein integrity. The RY3&4 domain is also referred 
to as phosphorylation domain and is a known site of phosphorylation which enhances the 
activity of RyR1(73). Ser2843 and Ser2814 of RY3&4 are well-studied residues that can get 
phosphorylated by PKA and CaMKII, respectively (73), and close to these and in the same 
domain we found oxPTMs Y2849/3NT (paper III, table 1) and Y2855/3NT (paper III, fig. 
3D).  
The spIA kinase and RyR (SPRY) domains of RyR1 mediate protein-protein interactions. 
The residues 671-681 of SPRY1 are involved in the binding of FKBP12 (73, 77). However, 
the exact residues that interact with FKBP12 are not yet fully elucidated and additional 
residues and even domains may also play a role in FKBP12’s affinity to RyR1. In SPRY1 we 
found oxPTM Y808/3NT. SPRY2&3, comprising residues 1055-1656, contains the divergent 
region two (DR2) (residues 1298-1431(73)). The DR2 region plays an essential role in ECC. 
Deletion or substitution of the amino acids in the DR2 region has led to an inability to 
propagate ECC (73, 164). It is exactly in this region, we identified oxPTMs Y1332/3NT and 
Q1401/MDA (paper III fig. 2A & table 1).  
RyR1 activity is inhibited by CaM at high [Ca2+]cyt  (161). CaM binds at three proposed 
binding domains (CaMBD) of the receptor (paper III, fig. 4A): CaMBD1 within residues 
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1975-1999 in the Junctional Solenoid (JSol), CaMBD2 within residues 3614-3640 in the 
BSol & Shell-Core linker peptide (SCLP) and CaMBD3 within residues 4295-4325, adjacent 
to the transmembrane helices(73, 165). The crystal structure of these domains has not yet 
been fully elucidated. However, it is clear that in RyR1 incubated in SIN-1, Q2017/MDA and 
Y2128/3NT of the JSol (paper III, fig. 3G) are close to CaMBD1 (paper III, fig. 4B-C).  
RyR1 belongs to the group of the six-transmembrane (6-TM) ion channels (73). The core, or 
also called transmembrane part, has 6 helices that span the plasma membrane of the 
sarcoplasmic reticulum (S1-S6). In comparison to receptors of the group, e.g. transient-
receptor potential (TRP) channels and voltage-gated potassium channels, RyR1 has an 
extraordinarily large cytosolic shell compared to the core (73, 74, 77). The voltage sensing 
domain is crucial for the voltage sensing function in other receptors of the 6-TM group and 
plays therefore an essential role in channel gating. However, in RyR1 the voltage sensing 
domain is not positively charged and therefore this domain has no voltage sensing function. 
Instead, the thus called pseudo voltage domain of RyR1 (also VSD-like domain), is thought 
to allosterically couple through mechanical conformational changes and thereby plays a role 
in RyR1 gating (73). It is in this domain, we found Y4687 and Y4554 modified with a 3NT 
modification close to the transmembrane helices (paper III, fig. 5E). Moreover, Y4554/3NT 
is closely located to CaMBD3 (paper III, fig. 4C). SIN-1 also induced oxPTMs in the core, 
in the SLCP domain (N3651/MDA, Y3657/3NT), the Core Solenoid (Y3765/3NT, 
Q3781/MDA) and in the Thumb and Forefinger (TaF) domain (Y4194/3NT) (paper III, fig. 
5B-E). Thus, now we have identified where the modifications are and that they alter channel 
gating. For future studies would site-directed mutagenesis in combination with single channel 
recordings and cryo-EM be powerful tools to further elucidate how these oxPTMs affect the 
RyR1 function.  
4.2.3 FKBP12 dissociation  
The 12kDa protein FKBP12 binds to RyR1 and stabilize the channel. Removal of FKBP12 
results in an increased open probability of the receptor (166). The RyR1 domains SPRY1 
together with NTD, SPRY2&3 and JSol are thought to form a cleft for FKBP12 binding 
which binds with a stoichiometry of four FKBP12 proteins per RyR1 homotetramer (77, 78, 
166). Oxidative stress on RyR1 has been associated with FKBP12 dissociation (7, 140, 158) 
and our mass spectrometry analysis on RyR1 incubated in SIN-1, identified oxPTM 
N84/MDA (NTD), H379/MDA (NTD), 249 Y808/3NT (SPRY1), Y1081/3NT (SPRY2&3), 
H1254/MDA (SPRY2&3), Q2107/MDA 250 (JSol) and Y2128/3NT (JSol) which were 
localized to the FKBP12 binding region (paper III, fig. 6B-C). As proof-of-concept, these 
modifications resulted in reduced FKBP12 bound to RyR1 with up to ~50% less FKBP12 
bound to RyR1 after SIN-1 treatment as shown by immunoblotting experiments (paper III, 
fig. 6D-E).  
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4.2.4 3NT and MDA modifications on RyR1 from muscle affected by arthritis 
Our results show that 3NT and MDA modifications are directly linked to increased RyR1 
open probability and that oxPTMs are introduced in specific regions that could interfere with 
the gating of the channel. Increased RyR1 open probability, FKBP12 dissociation and Ca2+ 
leak are associated with reduced SR Ca2+ load and reduced SR Ca2+ release during ECC 
which could ultimately lead to impaired muscle contractility (7, 29, 83, 84, 140). Based on 
that oxidative stress on RyR1 is linked to the pathological process of many diseases, 
including RA (19) and cancer (7), and since higher levels of 3NT oxPTMs have been 
observed on the RyR1-DHPR super-complex in association with arthritis (2), we aimed at 
identifying oxPTMs on RyR1 from skeletal muscle affected by CFA-induced arthritis. 
However, we have so far not been able to identify 3NT and MDA oxPTMs on RyR1 from the 
arthritis affected muscles. In fact, that was almost expected since we had previously 
concluded that muscle weakness in mice with CFA-induced arthritis is caused by a 
myofibrillar problem (section 4.1.1 & 4.1.2) rather than a Ca2+ release complication. 
However, based on that stress associated PTMs on RyR1 (and RyR2 in cardiac) have most 
often been observed in more severe conditions (e.g. breast cancer-derived bone metastases(7), 
ventilator-induced muscle weakness (167) and heart failure (168), hence we believe that 
oxPTMs on RyR1 and altered Ca2+ release will appear in a later, more severe, stage of muscle 
weakness associated with RA (and here CFA). Nevertheless, the results from this study 
provide important information for continued efforts to understand RyR1 gating and the role 
of oxidative stress on RyR1 in pathophysiological conditions where oxidative stress and 
intrinsic muscle weakness play a role.  
4.3 SOURCES AND SCAVENGERS OF ROS IN SKELETAL MUSCLES 
AFFECTED BY ARTHRITIS (PAPER IV) 
Oxidative stress can be caused by an imbalance between the synthesis and scavenging of 
ROS (2, 3, 19, 36). Since we have shown that oxidative stress associated with RA promotes 
muscle weakness through introduction of oxPTMs on actin, we hypothesized that the balance 
between ROS sources and ROS scavengers is altered in muscles affected by arthritis. To test 
this hypothesis, we aimed to characterize the intramuscular pathways that underly oxidative 
stress in arthritis and contribute to muscle dysfunction. To that purpose we have looked at 
well-known sources of ROS and their respective scavengers in skeletal muscles of mice with 
CFA-induced arthritis (paper IV).  
4.3.1 Decreased expression of mitochondrial complexes  
Mitochondria can produce O2
•- and H2O2 in skeletal muscle (37, 97). More precise, the 
mitochondrial complexes of the electron transport chain (ETC) can transfer electrons from their 
prosthetic group to O2 which causes the formation of O2
•- (96). Therefore, the protein and gene 
expression were investigated of the mitochondrial complexes in mouse skeletal muscle affected 
by arthritis (paper IV, fig. 1). As previously, arthritis was evoked in mice by unilateral injection 
of CFA in the ankle joint and mice were sacrificed after two weeks. At this time point, a drastic 
decrease in gene expression was observed for nuclear-encoded genes of the mitochondrial 
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complexes (I until IV) in the muscles of the arthritic leg compared to the healthy control leg 
(paper IV, fig. 1B). Simultaneously, the protein expression of complex I, II, IV and V was 
significantly decreased in the muscles affected by arthritis compared to the control muscles 
(paper IV, fig. 1C-D). The decrease in protein and gene expression of the mitochondrial 
complexes is indicative of a decreased oxidative phosphorylation capacity in muscles afflicted 
with arthritis.  
4.3.2 Increased expression of scavengers SOD2, catalase and GPX1 
O2
•- is, under normal circumstances, rapidly scavenged to H2O2 by SOD2 and subsequently 
converted to H2O and O2 by catalase and GPX1 (37). The gene and protein expression of SOD2, 
catalase and GPX1 were therefore analyzed in skeletal muscles affected by arthritis (CFA-
induced arthritis in the ankle) and compared with healthy control muscles. At the two-week time 
point, the protein expression of all three scavengers was significantly increased in muscle affected 
by arthritis compared to healthy control muscles (paper IV, fig. 1E-F). The gene expression of 
GPX1 was increased and that of SOD2 unchanged in the arthritis affected muscles (paper IV, 
suppl. fig. 1). At the same time, the gene expression of catalase was significantly lower in the 
arthritis-afflicted muscles. To check if the increased protein expression while decreased gene 
expression of catalase could resemble accumulation of inactive catalase, we also analyzed the 
catalase activity in both groups. However, the catalase activity was significantly higher in arthritis 
affected muscles than in healthy control muscles (paper IV, fig. 1G).  
4.3.3 Altered subcellular location of ROS scavenger in muscles affected by 
arthritis  
The previously described results suggest a higher ROS scavenging capacity in muscles 
afflicted with arthritis. The scavenging of O2
•- and H2O2 is dependent on the subcellular 
localization of ROS scavengers, as ROS interact with protein and cellular targets in their 
immediate proximity (157). Here we used immunofluorescent staining and super-resolution 
imaging in skeletal muscle fibers to determine the subcellular localization of the ROS 
scavengers SOD2 and catalase in skeletal muscle fibers from mice with CFA-induced 
arthritis and healthy controls. The location of the scavengers was compared relative to -
actinin, an anchoring protein in the z-line of the sarcomere which is responsible for 
mechanical integrity (169).  
SOD2 is a mitochondrial specific ROS scavenger (37) and electron microscopy from the 
striated skeletal muscle have shown that mitochondria are located at the z-line (170, 171). 
Indeed, in mice with CFA-induced arthritis, SOD2 expression could be observed at the Z-line 
in both muscle fibers affected by arthritis and healthy control muscle (paper IV, fig. 2A&B). 
On the other hand, SOD2 was also found expressed at the M-line at the center of the 
sarcomere in both arthritis affected muscle fibers and healthy control fibers. Whereas SOD2 
expression was generally increased, the distribution of SOD2 expression at either the Z or M-
line was not significantly affected by arthritis (paper IV, fig. 2C-E).   
Catalase was found expressed at the z-line of the sarcomere, adjacent to the z-line (z') and at 
the M-line in both muscle fibers affected by arthritis and healthy controls (paper IV, fig. 
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3A). The location of the z' expression of catalase is ~150nm from the z-line, likely 
corresponding to the position of the peroxisomes. In contrast to SOD2, the distribution of 
catalase was significantly different in the arthritis-affected muscle fibers compared to healthy 
control fibers. The catalase expression was namely more pronounced at the z'-line in muscle 
fibers from the arthritic leg compared to muscle fibers of the control leg (paper IV, fig. 3C-
E). The distance between peak catalase fluorescent intensity between Z and z'-line was 
therefore significantly reduced in the arthritis affected muscle fibers compared to healthy 
control fibers. 
The significant increase of SOD2 and catalase expression and decrease in expression of 
mitochondrial complexes, suggest an enhanced ROS scavenging capacity in skeletal muscle 
affected by arthritis. An increase of catalase at a subcellular location that is close to the 
mitochondria, would imply enhanced scavenging of H2O2 to H2O and O2. 
4.3.4 No increase of ROS production from mitochondria or NOX2 
To investigate the subcellular ROS production in muscles affected by arthritis, ROS 
production from both mitochondria and NOX2 were assessed with redox sensitive ROS 
probes (roGFP). roGFP probes have two advantages: firstly, they are genetically encoded 
towards a specific site of ROS production such as the mitochondria (mito-roGFP) or NOX2 
(p47phox-roGFP) (172). Secondly, roGFP probes are reversible: upon oxidation of their 
chromophore, mito-roGFP and p47phox-roGFP lose their excitability at 488nm which is 
reversible by reduction by for example DTT (172, 173). These probes thereby allowed us to 
follow ROS formation by the mitochondria and NOX2 in muscle fibers affected by arthritis 
in a three step protocol: first the baseline oxidation level in physiological Tyrode solution  
was established (i baseline), secondly the maximal fluorescence for each fiber was 
established with DTT (ii, DTT) and last the rate of oxidation was measured by quantifying 
the quenching of the roGFP probe over time after substituting Tyrode with DTT for fresh 
Tyrode (iii, post-DTT) (paper IV, fig. 4A & 5A).  
Mito-roGFP or p47phox-roGFP were transfected into the FDB muscle of mice one week 
prior to induction of arthritis with CFA in the ankle. The ROS production was measured in 
isolated FDB fibers of both the arthritic leg and control leg, 24h after the induction of 
arthritis, to measure ROS production at an early active phase of the inflammation. The 
baseline oxidation level of mito-roGFP was not significantly different between muscle fibers 
affected with arthritis compared to healthy control fibers (paper IV, fig. 4B). After fully 
reducing the fibers with DTT, the rate of mito-roGFP oxidation and thereby mitochondrial 
ROS production was significantly lower in muscle fibers from the arthritic leg compared to 
muscle fibers of the healthy control leg (paper IV, fig. 4C-E). The increased expression of 
SOD2 and catalase in the arthritis affected fibers would support the observed decreased rate 
of mitochondrial ROS formation in muscle fibers of the arthritic leg compared to fibers of the 
control leg of mice with CFA-induced arthritis. SOD2 has a fast rate constant for scavenging 
O2
•- to H2O2 (i.e. 2.3x10
9 M-1 s-1) (174). The rate of mitochondrial O2
•- production depends on 
the concentration of enzyme responsible for transfer of electrons to O2, the proportion of this 
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enzyme in a redox form that can react with O2, and the second-order rate constant for the 
reaction of the enzyme with O2 (96, 175). Mitochondrial complexes I and III are thought to 
facility the electron transfer to O2 for the formation of O2
•- in the mitochondria (37, 96, 175). 
This means that if the scavenging of mitochondrial produced O2
•- is enhanced, shown by the 
increased SOD2 expression in arthritis affected fibers, and the mitochondrial complex 
expression is decreased, then the net O2
•- production by the mitochondria in a balanced in-
vitro environment may indeed be lower in arthritis affected muscles. Alternatively, the 
increased SOD2 and catalase expression and activity remove the O2
•- and H2O2
 at a faster rate 
than can be detected with the mito-roGFP probe. This knowledge in combination with the 
observed increase in catalase activity and expression at subcellular locations close 
mitochondria, supports the observed decreased rate of mitochondrial ROS production in 
arthritis affected fibers.  
The ROS production from NOX2 was also significantly lower in arthritis affected muscle 
fibers compared to healthy control fibers. At baseline, the p47phox-roGFP fluorescence was 
significantly higher in the arthritis affected muscle fibers than in the healthy control fibers, 
showing that the probe was more reduced (paper IV, fig. 5A-B). The rate of ROS production 
by NOX2, after fully reducing the fiber with DTT, was significantly lower in arthritis 
affected fibers than in control fibers (paper IV, fig. 5C-E). In fact, the rate of ROS 
production by NOX2 in muscle fibers of the arthritic leg, was near zero. NOX2 is located in 
the sarcolemma and t-tubuli of the muscle and produces O2
•- extracellularly which is 
converted by SOD to H2O2 (176, 177). This H2O2 can cross the membrane to exert 
intracellular effects and can be scavenged by catalase (37, 96). The expression of NOX2 has 
previously been found increased in muscles from rats with adjuvant arthritis (AIA)(3). 
However, here no significant difference could be found in NOX2 protein expression between 
arthritis affected muscle fibers and healthy control fibers (paper IV, suppl. fig. 2A&B). 
Altogether, the results indicate that two of the primary considered sources of ROS production 
in skeletal muscle, are not the primary source of oxidative stress in the arthritis afflicted 
muscles of these mice. A result that is discussed further in the next section.  
4.3.5 Treatment of mice with arthritis with the SOD2/ catalase-mimetic EUK-
134 restores muscle force 
The mito-roGFP and p47-roGFP measurements of the rate of ROS production, indicate that 
the primary cause of oxidative-stress induced muscle weakness associated with arthritis is not 
the result of a net increased ROS production by the mitochondria or NOX2. However, 
treatment (2 weeks, once daily from the start of the induction of arthritis) of mice with CFA-
induced arthritis with EUK-134, a SOD/ catalase mimetic, counteracted muscle weakness 
(paper IV, fig. 6). In fact, it restored muscle force of the muscles afflicted with arthritis to 
levels similar of that of the control leg. These results are in agreement with earlier studies that 
showed that EUK-134 significantly improves skeletal muscle force in rats afflicted with a 
chronic inflammation (3, 178).  
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4.3.6 The sources and scavengers of ROS in skeletal muscles affected by 
RA: further studies are needed 
Altogether the results of paper IV provide data that we currently cannot fully explain. We and 
others have repeatedly shown that oxidative stress is present in serum (38, 39) and skeletal 
muscle (2, 3) affected by arthritis. Moreover, we have shown that oxidative stress can result 
in muscle weakness. However, in paper IV, we observed an enhanced ROS scavenging 
capacity and reduced ROS production in muscle fibers afflicted with arthritis. Nevertheless, 
treatment with an antioxidant that mimics SOD2/catalase was capable to counteract arthritis-
induced muscle weakness and we are currently investigating the oxidative stress levels in 
those muscles. However, two plausible explanations for our experimental results could be 
that in arthritis-afflicted muscles of CFA-mice (i.) the ROS production is increased but 
scavenged faster than the detection rate of the roGFP probes and/or (ii.) the source of ROS is 
different than mitochondria and NOX2 and close to that specific, yet unknown, site the ROS 
scavenging capacity is insufficient which results in oxidative stress and muscle weakness.   
Furthermore, thus far only the ROS production rate from mitochondria and NOX2 have been 
investigated, other examples of ROS sources are NOS and PLA2 as described in section 
1.4.2. Since EUK-134 is injected intra-peritoneally in mice with CFA-induced arthritis of this 
study, it is disseminated throughout the whole body of the mouse. It may therefore reach 
other sites of ROS production in the muscles where SOD2 or catalase are not efficiently 
neutralizing ROS, but we have so far no data to back up this hypothesis. 
We measured the ROS production at 24h after the induction of arthritis. Nathan et al. (36) 
carefully described the term oxidative stress: an imbalance in the production and scavenging 
of ROS which will, when at the wrong place, for too long and too high levels, lead to e.g. 
irreversibly impaired cellular function and/ or pathological gain of function. Hence the time 
dependency of oxidative stress needs to be studied further in muscles that are affected by 
arthritis.  
It is of importance to note that the rate of ROS production was measured in a balanced in 
vitro system. As mentioned in section 1.4.1, when the concentration of NADH increases, 
FMN of mitochondrial complex I can get more reduced whereby the production of O2
•- 
increases. An increase of NADHP is hypothesized to happen in case of decreased respiration, 
ischemia or low ATP demand as a consequence of low respiration (96). Measuring 
mitochondrial oxygen consumption rate with an Agilent Seahorse experiment and stressing 
mitochondria with FCCP may therefore provide a better understanding of how mitochondrial 
ROS production is affected in muscles affected by arthritis.  
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5 CONCLUSIONS  
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To conclude, muscle weakness is a comorbidity in patients with a chronic inflammatory disease 
as rheumatoid arthritis. Muscle weakness can reduce the ability to work and the quality of life 
for the afflicted persons. Muscle weakness cannot solely be attributed to a decrease in muscle 
mass. Instead muscle weakness in mice with arthritis and patients with RA is related to intrinsic 
muscle dysfunction that can be caused by oxPTMs on muscle proteins that are essential for 
force production, such as actin and RyR1. Stable oxPTMs 3NT and MDA on specific amino 
acid residues of actin and RyR1 respectively decrease myofibrillar force and impair actin 
polymerization and increase the open probability of RyR1. The primary sources and scavengers 
of ROS in pathological conditions as RA need to be further elucidated. Nevertheless, treatment 
of mice with arthritis with a SOD/catalase mimetic counteracts arthritis-induced muscle 
weakness. Furthermore, we included patients that were prescribed DMARDs and presented a 
low rheumatic disease activity, yet they exhibited oxidative stress and muscle weakness. This 
implies that muscle weakness is a comorbidity that cannot be counteracted by DMARDs (and 
glucocorticoids) alone and suggests that supplementary pharmacological treatment targeted to 
improve intrinsic muscle function is needed. There is currently a serious deficit in available 
clinical therapeutic approaches to counteract muscle weakness. However, the data presented 
here provide new leads for the development of such targeted treatments, i.e. EUK-134 is an 
interesting molecular scaffold for future therapeutic interventions to improve muscle function 
in RA patients. Altogether, the results of this thesis contribute to ultimately improving the 
quality of life for patients that suffer from muscle weakness caused by a chronic inflammatory 
disease such as rheumatoid arthritis. 
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